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ABSTRACT
CHARACTERIZATION OF PROMOTER REGIONS OF PAROTID GLAND
GENES
Sara M. Perez
July 9, 2013
BACKGROUND: Salivary secretion aids in digestion, host defense, and
lubrication. Parotid salivary gland defects from Sjogren’s Syndrome affect more
than one million Americans and cause dry mouth leading to oral disease. The
Amylase 1 gene and the PSP gene are markers of parotid gland differentiation
and indicate normal parotid gland function. Transcriptional activators of genes
involved in parotid differentiation have not been characterized.
HYPOTHESIS: Characterizing transcriptional activating sites in gene promoter
regions will confirm upstream activating factors in bioinformatic network
pathways.
METHODS: Two promoter regions of mouse amylase 1 were identified using the
ECR Browser, PCR amplified and ligated into a pGL4.10 luciferase vector.
Transcriptional repressor binding sites were identified and removed from the 1
kbp region, followed by PCR amplification to produce fragments that were ligated
into the minimal promoter pGL4.23 luciferase vector. These promoter clones
were then transfected into three cell lines and tested for promoter activity.
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Bioinformatic analysis of microarray data determined correlations between
increased transcription factor expression and markers of parotid differentiation. A
hypothetical transcription factor network was created. Two interactions from the
network predicted to activate the NUPR1 gene were Cited2/p300 and
IRF2/PCAF. Mist1 was suggested to activate the PSP gene based on the
hypothetical network. The promoter regions of NUPR1 and PSP were transfected
into a parotid acinar cell line, and promoter activity was determined using dual
luciferase assays with an internal Renilla control.
RESULTS: The four amylase promoter clones, R1, R2-R1, 900bp, and 700bp
were repressed as compared to a promoterless negative control, pGL4.10. The
NUPR1 promoter was not activated by the co-transfected combination of
Cited2/p300 or IRF2/PCAF. The PSP promoter alone was not activated by Mist1
transcription factor. However, PSP was activated when Mist1 was co-transfected
with Tcf3 transcription factor and when intron regions containing E-box binding
sites were added to the PSP promoter clone.
CONCLUSION: Amylase 1 was not activated in the regions tested; therefore the
active regions of the amylase 1 gene must be outside the 3 kbp region tested.
NUPR1 is not activated by the predicted interactions of Cited2/p300 or
IRF2/PCAF, so the results do not support the hypothetical transcription factor
network. The PSP proximal promoter is not activated by Mist1, but a PSP
promoter + intron construct is activated when the transcription factor Tcf3 + Mist1
are co-transfected.
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INTRODUCTION
SALIVARY GLAND
In mammals, there are three major types of salivary glands: the parotid
gland, the submandibular gland, and the sublingual glands; and there are minor
glands as well [1, 2]. The function of salivary glands is to secrete components
that make up saliva. A healthy adult secretes, on average, 500-1500 mL of saliva
per day [2, 3]. Saliva secretion can by stimulated by smell, taste, chewing,
psychological and hormonal status, drugs, age, hereditary influences, oral
hygiene, and physical activity.
Secretory cells in the salivary glands are specialized epithelial cells, and
are classified as serous cells, which secrete a watery fluid, or mucous cells which
secrete a mucin-rich fluid [2]. Each salivary gland secretes the components of
saliva from a cluster of cells termed acini, the main secretory unit. Acinar cell
secretions include water, electrolytes, mucus, enzymes, and other proteins [2].
Alpha-amylase is an enzyme secreted by acinar cells that breaks down starch
into glucose. Ductal cells are also contained in salivary glands and are involved
in modifying primary saliva and transporting saliva to the oral cavity [4].
Saliva is either secreted in response to a neural stimulus (regulated
secretion) or constitutively secreted from the apical membrane of acinar cells [5].
The saliva composition from regulated or constitutive secretion varies [2].
Regulated secretion is distinguished by large, dense secretory granules that
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contain 80 – 90% of the total proteins secreted from parotid acinar cells [6].
Constitutively secreted proteins are different from regulated secretion in that they
are contained in immature secretory granules that contain lysosomal and other
non-salivary proteins.
Water making up saliva crosses epithelial cells in an anion dependent
process [1]. Vesicles in the cell bring membrane ion transport proteins to the cell
membrane, and these proteins allow the movement of sodium, chloride, and
bicarbonate into the acini lumen [7]. The transport of these anions into acini
creates an osmotic gradient allowing the transport of water into the lumen. Water
helps complete saliva formation. Since water is a required component of saliva,
salivary glands require very high fluid transport per unit surface area [8, 9]. Water
channels called aquaporins have been found in salivary cells and aid in water
transport. Aquaporin-5 is located in the apical membrane of salivary cells. A
knockout model of aquaporin-5 decreased salivary fluid secretion by 50%,
indicating its importance in saliva formation [8].
Each type of salivary gland secretes a different type of saliva due to
different glandular content of serous cells and mucous cells [2]. The parotid gland
is located in subcutaneous tissue of the face overlying the mandibular ramus and
secretes serous type saliva containing the most abundant proteins of saliva:
amylase, proline-rich proteins, and parotid secretory protein (PSP) [1-3, 5]. The
sublingual gland is beneath the tongue and secretes a mucus substance. The
submandibular gland is found beneath the lower jaws and secretes a
combination of proteins and mucus. Other components present in the mixed
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saliva of the mouth, but not produced by salivary glands, are gingival crevicular
fluid, serum transudate from mucosa and inflammatory sites, epithelial and
immune cells, and microorganisms [2].
Saliva has a wide array of functions that protect the mouth against
infection by microorganisms. Saliva aids in host defense, digestion, and
lubrication [10]. Saliva lubricates the hard and soft oral surfaces with a saliva film
containing mucins, proline-rich-proteins (PRP’s), and water allowing for ease of
speech, mastication, and swallowing [11]. Saliva helps neutralize oral cavity pH
after food ingestion and removes food and microorganisms to maintain oral
hygiene [2]. Mucins in saliva bind to bacteria and prevent them from adhering to
the tooth enamel. Lysozyme in saliva also lyses bacteria and prevents rampant
growth of oral bacterial colonies. The binding of mucins and the action of
lysozymes, in combination with histatins and other proteins, aid in the
antibacterial and antiviral activities of saliva [12].
Salivary glands begin development in the embryo and go through
branching morphogenesis [13]. In the rat, parotid gland development begins
around the fourteenth day of gestation [14]. From this point the oral epithelium
thickens and grows into the mesenchyme as a bud. Epithelial cells proliferate
and begin the process of repeated branching and cleft formation. The lumen
develops and the gland differentiates into acinar and ductal components until the
mature parotid gland is formed [13, 14].
Parotid gland development can be divided into four stages. The first stage
is the prenatal period beginning at the initiation of gland development until birth.
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This period is characterized by cell proliferation, epithelial branching with terminal
clusters and ductal structures, and an absence of secretory granules [14]. The
next stage, neonatal period, is characterized by acinar cells differentiating to
active secretory cells. The transitional period has the complete adult morphology
and secretory proteins found in an adult gland. Acinar cells continue to grow in
size, rough endoplasmic reticulum content, and secretory granules. Ducts form
their elongated branching structure. The fully mature gland is found in the adult
period of parotid development.
Infection, inflammation, head and neck radiation therapy, medications, and
Sjögren’s Syndrome (SS) can compromise salivary gland function [5, 15].
Sjögren’s Syndrome is an autoimmune disease affecting the salivary and lacrimal
glands characterized by lymphoplasmocytic infiltration of the tissues [16].
Sjögren’s Syndrome can be classified as primary SS or secondary SS,
depending on the absence or presence of other connective tissue diseases.
About one-third of primary SS patients will develop malignant lymphoma.
Characteristic symptoms of Sjögren’s Syndrome include decreased tear
production by the lacrimal glands and xerostomia, or dry mouth, caused by
salivary gland dysfunction [17]. Xerostomia causes issues with mastication,
swallowing, and taste [3, 15]. More importantly, xerostomia can affect oral health
causing increased oral disease, such as periodontitis, and dental caries.
Diagnosing SS has been, and continues to be, a challenge. There are two
factors that clinicians must deal with when diagnosing a patient with SS:
assessing the ocular and salivary components of the disease and distinguishing
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between primary and secondary SS variants [18]. These two factors have led to
classification criteria that are not used consistently from clinician to clinician
around the world [18]. The American-European Group has revised and
established diagnostic criteria for SS [18, 19]. At least four out of six subjective
criteria and three out of four objective criteria must be met to diagnose SS. These
criteria include subjective and objective ocular dryness, subjective and objective
oral dryness, presence of Sjögren-specific antibody A (SSA) or Ro, and/or
Sjögren-specific antibody B (SSB) or La [18, 19].
Diagnostic testing for SS includes looking at saliva components
(sialochemistry) such as determining the presence of autoantibodies in saliva,
and/or looking at salivary flow rates (sialometry) of whole saliva or glandular
saliva [2, 20]. Limitations to analyzing saliva composition is that this can only
diagnose SS when major changes occur, and sialochemical analysis cannot
always be performed because amounts of saliva are insufficient to test [20].
Another test to assess salivary gland function is an invasive biopsy of minor
salivary gland tissue. This allows clinicians to evaluate the degree of
lymphoplasmocytic infiltration within the harvested glands and is an important
objective criterion in the diagnosis of SS [18]. The risks with biopsy are the
patient’s lip can be left numb after the procedure and false negatives can occur.
Once a patient is diagnosed with SS, the goal is to restore salivary gland
function. If there is still viable glandular tissue, cholinergic medications such as
pilocarpine and cevimeline will stimulate saliva production [3]. In addition,
artificial salivas and other oral hygiene products can help keep the mouth moist
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but some patients still struggle to find relief. Research is currently in progress
looking at salivary gland regeneration by expressing growth factors and
transcription factors expressed during development. Also, gene therapy using the
adenovirus-mediated water channel (aquaporin-1, AQP1) gene has shown
increased salivary flow rate in rats [3, 21]. The AdhAQP1 gene was expressed in
a miniature pig model that showed dose-dependent, transient increase in parotid
salivary flow [3, 22]. Baum et. al. have begun a Phase I clinical trial testing
AdhAQP1 in human subjects [23]. Through the first 42 days of this trial his group
has found the use of an Ad5 vector to be safe, an increase in parotid flow rate,
and the peak salivary flow rate is variable and occurs later than animal studies
[23]. This clinical trial holds hope for the use of gene therapy for parotid gland
dysfunction.
The lack of sufficient treatment for salivary gland dysfunction and initial
research for gene therapies support aims focusing to confirm gene expression
and transcription factor pathways involved during parotid gland differentiation.
These pathways could shed light on new diagnostics or therapeutics to help
patients suffering from parotid gland ablation. The research described and data
provided in this thesis was aimed at confirming a few of the many regulatory
pathways involved in parotid gland differentiation. The following sections will
describe genes that are markers of parotid gland terminal differentiation and
some of the transcription factors that regulate these genes.

'"

TRANSCRIPTION FACTORS EXPRESSED DURING PAROTID
DIFFERENTIATION
Molecular mechanisms are involved in parotid gland differentiation. Dr.
Venkatesh Srirangapatnam performed analysis of mRNA expression across the
process of rat parotid gland development. The heat map created from this
analysis observed changes of mRNA expression of transcription factors from
embryonic days to postnatal days (Figure 1). From this data, statistical analysis
combined similarly expressed groups of transcription factors in a hierarchical
clustering. This clustering observed four distinct stages of parotid differentiation.
The model suggested by the clustering is that transcription factors increased in
the first cluster turn on expression of transcription factors in subsequent clusters
eventually leading to activation of expression of gene markers of parotid
differentiation, such as amylase I and PSP. My goal has been to contribute to
defining the progressive regulatory steps that lead to expression of markers of
differentiation of the parotid.
The mRNA analysis, along with Ingenuity Pathway Assist (IPA) analysis,
was used to create a hypothetical network of transcription factors involved in
parotid differentiation. IPA is a system that analyzes a list of genes and helps
model gene interactions using a knowledge base of reported gene function [24].
Gene interactions generated by IPA were depicted in a hypothetical transcription
factor network (Figure 2). Some of these interactions were validated in the
laboratory, but some still needed to be confirmed. These pathways are the basis
of the research presented in this thesis. The goal of this research was to
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characterize promoter regions of parotid gland gene markers by validating the
transcription factor networks designated A, B, and C on the hypothetical
transcription factor network in Figure 2. The specific goals were to test the
promoter regulation of mus Amylase-1 gene, rat NUPR1 gene, and rat PSP gene
in a parotid acinar cell line. Analysis of transcription factor expression helped
suggest different regulatory pathways in parotid gland differentiation. This mRNA
expression analysis aided in selecting the gene promoters and the transcription
factor interactions studied. Also, amylase-1 and PSP have been cited in the
literature numerous times as markers of differentiated parotid acinar cells, so it
was important to identify the active promoter regions and/or activating
transcription factors involved in the expression of these genes. The goal of
confirming the activation of each promoter is described in the sections below.
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Figure 1: Transcription factor expression during parotid differentiation.
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Figure 1: Heat map of transcription factors expressed during parotid
differentiation. Each column represents an individual transcription factor mRNA.
Each row represents an individual rat parotid gland time point starting at
embryonic day 18 (E18) and ending at postnatal day 25 (P25), represented on
the right side of the heat map. The left side of the heat map is a hierarchical
clustering of similarly expressed transcription factors. Parotid differentiation can
be clustered in four groups according to this analysis. Transcription factors
expressed in low concentrations are represented by green and those expressed
in higher concentrations are represented by red. The model is that in some cases
transcription factors in the first cluster activate transcription factors in the second
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cluster and continues until the transcription factors eventually turn on markers of
differentiation, such as amylase I or parotid secretory protein, (PSP).
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Figure 2: Hypothetical transcription factor network regulating parotid
differentiation.
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Figure 2: This network shows transcriptional activators regulating parotid
differentiation based on Ingenuity Pathway Assist (IPA) analysis. Transcription
factor genes expressed differentially in parotid differentiation were of interest and
this pathway was created. The green arrows represent confirmed interactions.
The black arrows represent interactions that still need to be confirmed.
Experiments performed to confirm some of these interactions included testing the
interactions labeled A, B, and C.
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AMYLASE I GENE
Amylase is a marker of terminal differentiation of the parotid gland and is a
gene of interest in this research. Amylase has two genes located on mouse
chromosome three [25, 26]. The first locus corresponds to Amy-1, which is
strongly expressed in the salivary gland, and the second locus is Amy-2, which is
expressed in the pancreas. The Amy-1 gene is expressed as two different mRNA
products with one in the parotid gland and the other in the liver. The coding
sequence for liver and parotid alpha-amylase is the same with the 3’ nontranslated region and part of the 5’ non-translated region being identical. The
extreme 5’ leader sequence is unrelated with no sequence homology found
between parotid alpha-amylase and liver alpha-amylase. Mouse Amy-2 shares
90% homology to parotid and liver alpha-amylase, but it has a very short 5’
untranslated region and the coding region is shorter [27]. Amy-1 and Amy-2 both
have ten exons coding for alpha-amylase. However, Amy-1 has two exons
containing 5’ untranslated leader sequence corresponding to the parotid alphaamylase exon that is separated from the first coding exon by 7.8 kb, and the liver
alpha-amylase exon that is 4.9 kb from the first coding exon. Alpha-amylase
mRNA is about 10-fold less in parotid acinar cells than pancreatic cells [28]. Liver
alpha-amylase levels are even lower making up 1/100th of parotid levels and
1/1000th of pancreatic levels. Pancreatic amylase is expressed in all mammals,
but salivary amylase is specific to primates, rodents, and lagomorphs [29].
A chapter written describing murine alpha-amylase describes two Amy-1
promoters with tissue specific expression, the parotid promoter, PP, and the liver
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promoter, PL [28]. Endogenous RNA was isolated from rat liver and parotid cells
[26]. Rat liver and parotid mRNA were fractionated on a gel and hybridized to a
probe complementary to the first exon of the liver-specific mouse Amy-1 mRNA.
Liver-specific amylase transcripts were detected, but parotid-specific transcripts
were not detected. Next, rat liver and parotid mRNA was hybridized to a primer
complementary to most of the coding region of the parotid mRNA. This probe
detected large amounts of parotid-specific alpha-amylase transcripts. These
results confirm that amylase is being specifically transcribed in the liver and
parotid glands. Primer extensions assays used a radioactive labeled probe that
was hybridized to rat parotid mRNA and was extended to determine the location
of the transcription start site for parotid Amy-1 in the mouse and rat [26].
Experiments done in vitro helped validate the transcription start sites of the
parotid promoter and the liver promoter. Results from these experiments showed
that polymerase II molecules involved in transcription initiated at two different
start sites. Since the proximal upstream region to the transcription start site is
usually assumed to be the promoter, the parotid and liver amylase promoters
were predicted to be in these regions.
The parotid promoter was observed to be about 30-fold stronger than the
liver promoter in hepatocytes, giving the terms “strong promoter” to the parotid
(Pp) and “weak promoter” to the liver (PL). The liver promoter was active in liver,
parotid, and pancreas with no apparent physiological relevance of the liver
transcript in the parotid or pancreas. The transcriptional activity of the parotid
promoter increases alpha-amylase levels about 100-fold in the saliva of weaning
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rats to make up about 97% of amylase transcripts in adult saliva [30]. The liver
promoter is active soon after birth and by two weeks of age the activity of the
liver promoter is that which is found in the adult parotid. Transcripts produced
from PP are found in all acinar cells at three weeks of age.
The activity of mouse PP and PL was tested by transfecting the 1 kbp
proximal promoter region in cell lines that do not have endogenous Amy-1
expression [28]. The chapter mentioned above describing murine alpha-amylase
noted (but did not present data) on the activity of PL and PP. PL was active in
stably transfected mouse L cells, and was transiently expressed and activated in
many of the cell lines tested. Importantly, the endogenous PP had been found to
be about 30-fold in vivo more efficient than PL, but transfected PP promoter was
not active in any cell lines tested. The conclusion made from these experiments
was that PP is more controlled than PL, probably due to PL’s lower tissue
specificity and to its activity in less differentiated parotid acinar precursor cells.
Also, the results suggest that PP might be regulated by a repressive mechanism.
An unpublished observation mentioned by Schibler in the murine alpha-amylase
chapter was that the progressive deletion of the 5’ flanking region of PP found
that by removing nucleotides upstream of position -300 relieves the
transcriptional repression leading to promoter activation [28].
The human salivary amylase promoter was active in human
submandibular gland-derived cell line (HSG) [31]. The human 1 kbp amylase
promoter was inserted in an adenovirus containing a luciferase reporter gene.
Adenoviral infection of the HSG cell type with the human 1 kbp promoter
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construct observed that this promoter is active. The conclusion based on the
transfection studies just described is that the human parotid gland and the
murine parotid gland may involve different mechanisms that activate the parotid
amylase promoter.
Rat and mouse Amy-1 have some similarities and differences in gene
structure and in gene and tissue expression [28]. The similarities between the
species are they both contain two promoters, PP and PL, there is homology of
sequences around PP and PL, and PP expression is exclusive to parotid acinar
cells. The differences between the two species are that PP and PL are farther
apart in the rat, there is a different PL start site used, the rat splice donor sites are
downstream of the mouse site, and the mRNA is about 300 nucleotides longer
than the mouse. The PL is specific to the liver and is not detected in rat parotid
acinar cells.
Salivary alpha-amylase protein has various functions in the oral cavity
ranging from enzymatic activity to interactions with bacterial species as well as
making up other components that aid in tooth formation. Salivary amylase is an
abundant enzyme produced primarily from serous cells of the parotid. Human
saliva contains on average 0.04 – 0.4 mg/mL of amylase constituting up to 5% of
the total salivary protein content [32]. The enzymatic activity of salivary alphaamylase protein is to hydrolyze food starch into maltose and glucose [33].
Specifically salivary alpha-amylase hydrolyzes !-1,4-glucosidic bonds in starch,
glycogen, and other polysaccharides starting in the oral cavity [34]. Amylase
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enzyme has been shown to function as a monomeric or dimeric protein and
requires calcium and chloride ions for full enzymatic function [35, 36].
Salivary amylase indirectly and directly affects oral biofilms by providing
carbohydrate nutrients to bacteria, promoting bacterial adhesion to the tooth
surface, and binding to oral streptococci at secondary oligosaccharide sites [34,
36, 37]. When tooth surfaces are initially exposed to the oral environment, a thin
film absent of cells is formed called the acquired enamel pellicle (AEP) [32].
Amylase has been found as a component of the AEP.
Amylase is highly expressed in the adult parotid gland, so it is important to
understand how this gene is regulated [30]. Previous studies found the human
proximal parotid amylase promoter to be active, however, recent experiments
have observed repressed activity when testing the mouse and rat proximal 1kbp
promoter region and a 3 kbp promoter region. The most recent results suggest
that there might be an unidentified upstream activating element allowing
activation of the amylase I gene. The hypothesis for my work was that
transfecting amylase I promoter clones containing different promoter regions in
different cell types will activate the promoter region. Mouse and rat amylase I
promoter clones were made containing a 1 kbp proximal promoter region, and
one clone was made containing both the 1 kbp proximal promoter region and a 2
kbp region about 2.5 kbp upstream of the proximal promoter region of both the
mouse and rat amylase 1 gene. Sequence analysis of the mouse 1 kbp promoter
region identified transcriptional repressor binding sites. A 900 bp and a 700 bp
promoter clone were made with these sites removed. The promoter fragments
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were ligated into a luciferase reporter vector. The promoter clones were tested
for promoter activity by transient transfection studies, and were transfected in
three different cell types. The rat amylase promoter clones were transfected in a
parotid acinar cell type. Amylase promoter activity was measured by performing
assays that measured firefly luciferase expression, and transfection efficiency
was measured by performing assays measuring renilla luciferase expression.
The promoter activity was determined by normalizing firefly luciferase RLU
values to renilla luciferase RLU values.

NUPR1 GENE
NUPR1, nuclear protein 1, or p8, was first discovered as a gene activated
in the acute phase of pancreatitis [38]. It has been shown to have increased
levels in developing pancreas and liver [39]. Screening of human pancreatic
cDNA library characterized the NUPR1 gene as having three exons and two
introns with 5’ and 3’ untranslated regions, and the gene is located on
chromosome 16 [40]. The NUPR1 protein has a bipartite signal for nuclear
localization suggesting it functions in the nucleus. It also contains a basic helixturn-helix motif that allows the protein to bind DNA as a transcription factor [3840]. Mallo et. al. performed northern blot analysis to analyze NUPR1 mRNA [39].
They found NUPR1 was highly expressed in salivary glands and expressed to a
lesser extent in stomach, colon, liver, and kidneys. The brain, spleen, testes,
thymus, and skeletal muscles all had an absence of NUPR1 mRNA. Tissues
expressing NUPR1 only express this gene in exocrine cells [39]. The NUPR1
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gene has been further characterized by parotid gland mRNA analysis as well as
data showing high NUPR1 expression in salivary glands, localization of
expression in acinar cells.
NUPR1 gene expression has not been characterized in parotid gland
differentiation. NUPR1 mRNA had elevated expression in the analysis of
transcription factors involved in parotid gland differentiation. Transcription factors
that increased in expression at the same time as NUPR1 were tested as possible
activators of NUPR1 gene expression. These transcription factors included
Cited2 and IRF-2. A detailed explanation of these transcription factors and the
co-factors p300 and PCAF are described in following sections. The hypothesis
for this section of the research was that NUPR1 promoter activity would increase
when a Cited2/p300 combination or an IRF-2/PCAF combination is cotransfected. The cDNA combinations and the NUPR1 promoter driving luciferase
were transiently expressed in ParC10 and 3T3-L1 cells to determine promoter
activity.

PAROTID SECRETORY PROTEIN
Parotid secretory protein (PSP) was first identified as a leucine-rich protein
in rat saliva samples, and was later found as a major protein component of
mouse saliva [41]. PSP is found located on mouse chromosome two and on rat
chromosome three. Murine PSP is first detected in embryonic terminal clusters
and lumina, and the levels continue to increase throughout development,
reaching high levels in the adult gland [14]. PSP is an abundant product of
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mouse parotid acinar cells, and is found in low levels in sublingual serous cells
[4]. The mRNA levels of PSP in parotid acinar cells is about 10% of the total
cellular mRNA and about ten fold lower in sublingual glands [4, 42]. Poulsen et.
al. performed northern blot analysis of mouse tissue and quantified PSP mRNA
expression in various tissues [30]. They found the mouse parotid gland had the
most abundant PSP mRNA, with lesser amounts found in submandibular and
sublingual glands, even lower amounts in the pancreas, and undetectable
amounts in the liver. Another finding from this experiment was that the tissue
specific expression of mouse PSP parallels levels of mouse amylase expression.
The conclusion from this data is that PSP and amylase are expressed in the
mouse parotid gland. In humans, PSP mRNA expression is found in the
submandibular and parotid glands [43].
PSP belongs to the PLUNC (palate, lung, and nasal epithelium clone)
protein family, which consists of mucosal secretory proteins [44]. Specifically,
rodent PSP is the orthologue of the human PLUNC protein, SPLUNC2 [45].
PLUNC proteins are related to the BPI/LBP/CTEP lipid-binding protein family.
Bactericidal/permeability-increasing protein (BPI) and lipopolysaccharide binding
protein (LBP) bind lipopolysaccharide (LPS) constituents of bacterial cells walls
on Gram-negative bacteria, lipoteichoic acids of Gram-positive bacteria, and
lipoarabinomannas of mycobacteria [46]. LPS receptors of macrophages and
neutrophils recognize LPS bound to BPI or LBP and result in a cellular response
that destroys the invading pathogen or renders the pathogen inactive [43]. Since
PSP, PLUNC, and BPI/LBP proteins are related, it has been suggested that PSP
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may function similarly to the BPI/LBP proteins. These predicted functions include
binding to bacteria and having an antibacterial effect, having growth-suppression
effects on bacteria, promoting anti-inflammatory effects, and causing bacterial
agglutination [45]. Gorr et. al. expressed PSP in the rat cell line GH4C1 to test
PSP antibacterial activity [47]. Their data resulted in reduced colony numbers of
Pseudomonas aeruginosa supporting evidence for PSP bactericidal activity, and
they also observed reduced E. coli colony numbers presumably due to PSP
enhancing bacterial agglutination. This data support the idea of PSP being
antibacterial and helping agglutinate bacteria.
Nothing is known about the characterization of the PSP gene. A significant
goal of this work is to determine transcription factors that enhance PSP promoter
activity. Mist1 was a transcription factor predicted in the hypothetical network to
activate the PSP gene. The hypothesis was that Mist1 transcription factor or a
Mist1/Tcf3 transcription factor combination will activate the PSP promoter. The
goals of PSP promoter experiments were to determine if Mist1 activates the PSP
promoter, and to determine if mutating Mist1 DNA binding sites, or E-box
sequences (described in the following sections), will prevent PSP promoter
activation. Another goal of testing PSP gene activation was to test the affect of
Mist1 on other locations of the PSP gene. One group found that Mist1 activated
the Mindbomb 1 gene (Mib1) through the first intron [48]. E-box binding sites
were found in the second and third introns of the PSP gene. This region was
ligated into a PSP promoter-luciferase clone, and transient transfection studies
were performed to test Mist1’s affect on the PSP promoter + intron clone. The
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next goal was to co-transfect the E-protein, Tcf3, with Mist1 to see the
combinatorial effect of the transcription factors on the PSP promoter and PSP
promoter + intron.

CITED2 AND P300 TRANSCRIPTIONAL CO-ACTIVATORS
In the hypothetical transcription factor network, Cited2 was predicted to
activate NUPR1 gene expression. Cited2 belongs to a family of genes known as
CITED (cAMP response element binding protein (CBP)/p300 interacting
transactivators with ED-rich termini) [49, 50]. These proteins do not bind DNA,
but serve as transcriptional co-activators. Cellular Cited2 binds tightly to the
CBP/p300 transcription complex, and in turn the CBP/p300 complex binds to
DNA bound transcription factors to facilitate RNA polymerase II gene
transcription [51]. Interaction of Cited2 protein with CBP/p300 regulates
pathways influenced by this transcription complex such as co-activation of the
transcription factor AP2 [49]. Cited2 protein is involved in organogenesis, and the
early stages of adrenal tissue growth and adrenal differentiation [50, 52]. Also,
studies performed by Bamforth et. al. used Cited2 null mouse embryos to
determine how the absence of Cited2 caused complications in cardiac, neural
crest, and neural tube development [53]. They used in vitro binding assays and
found the C-terminal end of Cited2 interacts with the transcription factor Tfap2, a
factor involved in neural crest and neural tube development. To confirm Cited2
enhances target gene transcription by Tfap2, transient transfection studies found
that the activity of a luciferase reporter vector containing Tfap2 binding elements
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increased when Tfap2 and Cited2 were co-expressed, as compared to
expression of Tfap2 alone. These experiments confirmed that Cited2 is required
for proper development of the neural crest.
The nuclear phosphoproteins, p300 and cAMP response element binding
protein (CBP), are homologous and widely expressed [54, 55]. p300 is a coactivator that links DNA-bound transcriptional activators to the basal transcription
machinery. It has histone acetyltransferase (HAT) activity that is involved in
modifying chromatin structure within gene promoters, and the HAT activity also
allows p300 to increase DNA binding efficiency of p300-interacting transcription
factors [56, 57]. Both of these histone modifying actions result in more efficient
transcription of target genes. One example of p300 enhancing transcriptional
activity of skeletal muscle specific genes is by acetylating the transactivation
domain of myocyte enhancer factor 2 (MEF2) to increase its DNA binding ability
[56]. Also, nuclear hormone receptors like the thyroid hormone receptor have
enhanced transcriptional activity in the presence of p300 [58]. The bHLH skeletal
muscle transcription factor, MyoD, requires p300 to fully activate gene promoter
targets [57, 59-61]. These examples of p300 helping activate transcriptional
activation support the co-expression of p300 with Cited2 in the experiments
performed in the research described in this thesis.
Cited2 was of interest in the following research because its mRNA levels
increased about the same time as NUPR1 mRNA levels during parotid
development. The co-activator, p300, was of interest because it has been cited
numerous times in the literature as having interactions with Cited2 to enhance
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gene activation. The hypothesis was that a combination of Cited2/p300 would
increase NUPR1 promoter activity. Transient transfection experiments in ParC10
and 3T3-L1 cell types were performed to test the effect of the Cited2/p300
combination on NUPR1 activity.

IRF2 TRANSCRIPTION FACTOR AND PCAF CO-FACTOR
IRF2 belongs to the interferon regulatory (IRF) transcription factor family.
This transcription factor shares sequence homology to the IRF-1 gene in the 5’
half of the protein coding region [62]. IRF2 is a nuclear factor that binds various
DNA elements. One of these elements in called IRF-E and the consensus
sequence is G(A)AAAG/CT/CGAAAG/CT/C [63]. Another sequence IRF-2 binds
is the interferon consensus sequence (ICS), also know as the interferon
stimulated response element (ISRE), and the DNA binding sequence for this
element is A/GNGAAANNGAAACT [64, 65]. One last element IRF-2 binds is
known as the positive regulatory domain I (PRDI) of the IFN-" gene [66].
IRF-2 is a very stable protein with an eight-hour half-life [67]. The Cterminal domain of IRF-2 is rich in basic amino acids and contains a repression
domain [65]. The DNA binding activity is found in the N-terminal domain and
consists of three !-helices, four-stranded antiparallel "-sheets, and three long
loops [62]. This structure is similar to the binding domain of bHLH proteins
(described in a later section), however, the DNA interaction between these two
protein families differ [68]. The third !-helix of IRF-2 binds the major groove
containing the GAAA portion of the IRF-E or ICS binding sites while the other
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binding domain segments interact with the surrounding sequence.
Phosphorylation by protein kinase A (PKA), protein kinase C (PKC), and casein
kinase II (CK2) at multiple serine sites affect IRF-2 regulation during cell growth
[69].
IRF-2 can act as a transcriptional repressor or a transcriptional activator.
Proteolytic cleavage of IRF-2 is induced by interferons, viral infection, or dsRNA
treatment and becomes a transcriptional activator or repressor [65]. Once IRF2 is
efficiently expressed it represses interferon-stimulated response elements in
other genes induced by the interferon stimulus, such as IRF-1 [70]. Hamada et.
al. performed transfection experiments comparing the effects of IRF-1 and IRF-2
on IFN-" promoter expression in cell culture [62]. This promoter was activated by
IRF-1 alone, repressed by IRF-2 alone, and when there was co-expression of
IRF-1 and IRF-2 the promoter was repressed. The conclusion from this
experiment was that IRF-2 silences IRF-1. Genes that are activated by IRF-2 are
the vascular cell adhesion molecule-1 (VACM-1) gene, and the human H4
histone gene [71, 72]. Jesse et. al. observed the activation of the VCAM-1 gene
by IRF-2 in the IRF-E sequence of the gene promoter. Their data indicated that
the basic repression domain in the COOH-terminal end was inactive in
myoblasts, and that an acidic latent activation domain resides in the central
region of the protein. IRF-2 is also involved in cell cycle growth control and cell
cycle progression as a transcriptional activator of the human H4 histone gene,
FO108 [69].
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The transcriptional cofactor p300/CBP-associated factor (PCAF) is mainly
located in the nucleus and has histone acetyltransferase (HAT) activity [73-75].
The acetylation occurs post-translationally on the N#-amino-group of a lysine
residue [76]. These modifications influence protein functions such as proteinprotein interactions, protein association with DNA, and protein stability. PCAF is
a subunit of the SAGA-type multi-protein complex that functions as a co-activator
of transcription. Transcription is stimulated by the acetyltransferase activity of the
complex leading to modification of nucleosomes through interaction with
nucleosome remodeling enzymes.
PCAF has numerous targets that regulate different pathways in the body.
A few proteins that PCAF targets are tumor suppressors, and modification of
these proteins decreases cell growth [73]. The tumor suppressor p53 is
acetylated and activated upon DNA damage by PCAF to slow down cell growth
and promote apoptosis [77]. Other proteins involved in tumor suppression are
p73, which functions similarly to p53, and Bax proteins that mediate apoptosis
[74, 78]. Contrary to these tumor suppressor targets, PCAF also activates tumor
activator protein c-Myc by increasing its stability, which could be one cause of its
characteristic overexpression in cancer [79]. Acetylation of the tumor suppressor
protein PTEN decreases its potential to inhibit cell cycle progression [80]. An
instance where PCAF is required as an activator in non-cancer associated
context is by enhancing the activity of the estrogen receptor, the glucocorticoid
receptor, and the androgen receptor when the appropriate ligand for these
receptors is present [81]. PCAF has been shown to be required for progestin
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induction of target genes [75]. Also, PCAF acetylates and activates the
retinoblastoma protein to promote differentiation and to keep this protein
localized to the nucleus [82].
IRF-2 has been shown to recruit PCAF in order to enhance its own binding
to the ISRE [83]. DNA affinity binding assays and immunoblot assay performed
by Masumi et. al. found that IRF-2 directly binds PCAF in order to bind the ISRE.
Assays testing the enzymatic activity of PCAF on the ISRE-IRF-2 complex found
PCAF is a major contributor to acetylation in this complex. This group also found
that PCAF binds the internal DNA-binding domain of IRF-2 using C-terminal
truncations of IRF-2. The C-terminal domain of PCAF contains the histone
acetylase catalytic domain and a bromodomain, and in vitro experiments support
that the bromodomain of PCAF is where IRF-2 binds. IRF-2 has been shown to
activate the H4 gene, so Masumi et. al. ligated the H4 ISRE binding site to a
luciferase reporter vector to test promoter activation from IRF-2 and PCAF. The
combination of IRF-2 and PCAF yielded higher luciferase activity than IRF-2
alone indicating that PCAF is a co-activator for IRF-2.
In this thesis, the IRF-2 transcription factor was studied to determine its
effect on the NUPR1 promoter. The mRNA analysis of transcription factors
involved in parotid gland differentiation showed that IRF-2 is at elevated levels as
NUPR1 levels increase. This IRF-2 mRNA analysis and the study showing that
IRF-2 and PCAF interact and enhance promoter activation led to the decision to
co-express this transcription factor and co-activator with the NUPR1 promoter.
The hypothesis was that a combination of IRF-2/PCAF would increase NUPR1
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promoter activity. This was accomplished by performing transient transfection
experiments co-expressing NUPR1 promoter driving luciferase, and the IRF2/PCAF combination in 3T3-L1 cells.

MIST1 TRANSCRIPTION FACTOR
Mist1 belongs to the basic helix-loop-helix (bHLH) transcription factor
family, specifically class II bHLH proteins [84, 85]. The bHLH protein family is
large and has been organized into different classes (I-VII), each class referring to
their tissue expression, DNA-binding abilities, and dimerization properties. These
proteins are widely expressed in tissues, form homodimers or heterodimers with
other bHLH family members, and bind exclusively to E-box consensus sites [85,
86]. The bHLH-motif contains two amphipathic !-helices separated by a variable
loop region with a basic region that binds DNA [84]. Dimerization of bHLH
transcription factors allows the basic domains to interact and bind the E-box DNA
sequence, -CANNTG-, to promote activation of most genes [86-88]. Dimers of
bHLH proteins will line up with the E-box DNA sequence so one monomer
interacts with one half-site, CAN, and the other monomer interacts with the NTG
half-site [85]. Evidence has determined bHLH transcription factors can be “tissuespecific” or “ubiquitous”, and family members will have differential expression
during development.
Mist1 shares the same bHLH-motif as other bHLH family members, but
has a unique C- and N-terminal domain [84]. The N-terminal domain (repressor
domain) has been shown to negatively regulate bHLH-mediated transcription
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[89]. Translocation to the nucleus and formation of homodimers and
heterodimers with E-proteins allows Mist1 to bind E-box consensus DNA binding
sites and activate or repress gene expression depending on cellular contexts [84,
90].
Mist1 expression has been found in different species such as mouse, rat,
human, and zebrafish [90]. Pin et. al. used a “knock-out” mouse model by
replacing a coding region of the Mist1 locus with the bacterial LacZ gene to follow
Mist1 mRNA expression and to identify cells that accumulate Mist1 protein [91].
This model was used to create a Mist1-LacZ mouse line. Tissues from these
mice were stained for "-galactosidase (LacZ) to measure levels of Mist1 mRNA
expression is different tissues. LacZ expression indicated Mist1 positive tissues.
Assays testing Mist1-LacZ mice measured about a 1000-fold increase in LacZ
expression in pancreatic and salivary gland tissues compared to Mist1 negative
kidney tissue. Mist1 is present in pancreas, parotid gland, submandibular gland,
small intestine, male reproductive tract, and stomach secretory cells (mucussecreting cells, parietal cells, and chief cells) because LacZ was also expressed.
Mist1 specific polyclonal antibodies were used to examine protein expression in
cells. Mist1 was found located specifically in exocrine cells throughout the body
with high levels found in pancreatic acinar cells and in salivary glands;
specifically in serous cells of the parotid gland and seromucous type cells in the
submandibular gland. Cells in the sublingual gland, ductal cells, and endocrine
cells were negative for Mist1. Based on work by other groups, other tissues
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found to express Mist1 are chief cells in the stomach, mammary glands, seminal
vesicles, and lacrimal glands [90, 92].
Mist1 knockout studies have suggested Mist1 as a regulator of acinar cell
polarity and secretory granule formation. Calcium signaling complexes were
observed in acinar cells of Mist1 null mice [93]. Calcium signaling is polarized
from the apical-to-basal end of exocrine secretory cells and the localization of the
calcium signaling complexes and intracellular organelles are important for proper
calcium signaling. Digestive enzyme secretion in the pancreas is activated by
calcium, and disruption of the calcium signaling of this process has been shown
in acute pancreatitis. Mist1 is required for the normal development of serous
acinar cells in the pancreas and salivary glands. Mist1 knockout acinar cells have
altered calcium signaling due to the mislocalization and aberrant calcium uptake
by the mitochondria, which is a key player in controlling the calcium wave from
the apical-to-basal end of the cell. The digestive enzyme content in Mist1 null
cells is about 2.5 to 3-fold less in amylase, trypsin, and lipase as compared to
wildtype cells, which may be due to a diffuse and fragmented Golgi apparatus.
Changing calcium levels in a functioning cell are a major stimulator of exocytosis
in pancreatic acini. Stimulated amylase secretion was measured to quantify
exocytosis and found that exocytosis was impaired in the Mist1 knockout acinar
cells. This result suggested that the lack of exocytosis is due to secretory
granules are being mislocated and the calcium signaling complexes were
impaired. The study findings just described suggest Mist1 is involved in
controlling the localization and integrity of mitochondria and the Golgi apparatus
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and it controls the localization of secretory granules. The findings further support
the importance of Mist1 in correct acinar cell formation with properly localized
intracellular organelles involved in the apical-to-basal calcium oscillations and
waves important to cell function.
Another use of the Mist1 null mice model was studying the effect Mist1
has on Ras-like small GTPases, such as RAB3D and RAB26, that regulate
vesicular formation and transport [94]. A chief cell type was studied, the
zymogenic cell lineage (ZC), which is a cell located in the base of the gastric unit.
Mist1 expression has been shown to begin in easrly stages of ZC differentiation
and is involved in the formation and maintenance of secretory granules and
apical-basal reorganization. Mist1 null ZC’s were observed to have smaller
zymogen-containing vesicles and defects in the apical-to-basal organization.
Granules are usually found predominately in the apical end of the cell, but the
granules in Mist1 null cells were equally distributed in the apical and basal ends.
Inappropriate granule trafficking resulted at the basal end, and the nucleus was
localized at the apical end. The proteins RAB3D and RAB26 are involved in large
granule formation in the gastric epithelial cells. Mist1 was shown to directly bind
these RAB proteins in vitro by ChIP analysis on a cell line stably expression
Mist1-eGFP. In situ hybridization found RAB3D and RAB26 expression is
confined to Mist1 expressing ZCs in wildtpye mice, and laser-capture
microdissection (LCM) determined that Mist1 null ZCs had barely detectable
levels of RAB26 as compared to background levels, and the RAB3D expression
was significantly decreased. These in vivo experiments confirmed that Mist1
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transcriptionally regulates these RABs. These experiments further suggest Mist1
is important to proper secretory granule formation and for proper organelle
localization.
The majority of information on parotid secretory protein (PSP) focuses on
the protein functions in saliva, but there is not as much information on gene
expression of PSP gene. The PSP proximal promoter region has not been
characterized. Previous analysis of rat parotid mRNA showed patterns of
transcription factors involved in parotid gland differentiation. Mist1 was a
transcription factor that had elevated levels as PSP was being expressed. Also,
Mist1 DNA binding sites, or E-box sites, were found upon analysis of the PSP
promoter sequence. This led to my hypothesis that Mist1 would activate the PSP
promoter. The specific aims focusing on proving this hypothesis were to
determine if Mist1 activates the PSP proximal promoter, and to determine if
mutating E-box sites would prevent Mist1 activation. Transient transfection
studies co-expressing rat Mist1 cDNA with rat PSP promoter DNA were used to
accomplish these goals.

E2A (Tcf3) TRANSCRIPTION FACTOR
E2A belongs to the class I bHLH and the E-protein family [86]. The E2A
gene, also referred to as Tcf3, encodes two class I bHLH transcription factors,
E12 and E47, and the isoforms have been shown to form a heterodimer with
Mist1 transcription factor [84-86, 95]. The bHLH-motif of E12 and E47 have
conserved residues sharing sequence homology with the Drosophila proteins
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Daughterless, MyoD, and the Myc transcription factor family [85]. The HLH motif
provides a dimerization domain of two amphipathic !-helices separated by a
flexible loop [85]. The E47 dimer forms a four-helix bundle which allows the basic
region of the bHLH-motif to contact the major groove of DNA as loop residues
and one of the helices contacts DNA surrounding that region [96]. E2A binds Ebox consensus sequences, and this site promotes cell-specific gene expression
by regulating promoter and enhancer regions for specific gene expression in
muscle, pancreatic, and neuronal cells [85]. This transcription factor is widely
expressed in tissues and can act as a transcriptional activator or repressor
depending on its binding partner and other co-activators or co-repressors [86].
There are many functions of E2A transcription factor. E2A is essential for
B-cell development and activates genes involved in this process [85, 88, 95]. The
two proteins encoded by the E2A gene, E12 and E47, are essential for the
progression of early B cells past the very early progenitor stage [95]. The murine
mb-1 promoter was studied to understand the control for tissue and
differentiation stage-specific transcription in B cell development. E2A isoforms
have been shown to bind E-box sequences in this promoter and are required for
its activation. Genes specific to pancreatic development contain E-box
sequences and require the heterodimer formation of E2A and the class II bHLH
BETA2 for pancreatic differentiation [85]. One E2A function that has been
suggested is its role in tumor suppression [97]. Mice that were deficient in E2A
rapidly developed T-cell lymphomas and loss of E2A homodimers appeared to
have a role in T-cell leukemia development. The ectopic expression of E2A in
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mice lacking this transcription factor induced apoptosis and therefore supports its
role in tumor suppression. Another way E2A enhances gene activation is by
interacting with cofactors such as p300, CBP, and PCAF in the AD1 and AD2
activation domains in the N-terminal [88, 98]. Both the E12 and E47 proteins
have been shown to recruit p300, a co-activator with histone acetyltransferase
activity involved in chromatin remodeling, and this interaction enhances
transcriptional activity [98].
There are also instances of repression by E2A isoforms. The E12/E47
heterodimer have been shown to repress activity on cell-cell adhesion protein Ecadherin during epithelial-mesenchymal-transition (EMT) of embryonic tissue
development and of metastases [86, 88, 99]. Also, binding with the class V bHLH
protein, Id, negatively regulates E-protein transcriptional activity. Id proteins lack
the basic domain that would bind DNA in target promoters, and this blocks the
transcriptional activity of the bound E-protein [100].
Mist1 transcription factor alone repressed PSP promoter activity. Tcf3
transcription factor was utilized as a binding partner for Mist1 in experiments
testing the activity of PSP promoter and PSP promoter + intron activity. The
hypothesis was that co-transfection of Mist1 and Tcf3 would increase PSP
promoter and/or PSP promoter + intron activity. The goals were to determine how
the PSP promoter and the PSP promoter + intron clones were affected by the
Mist1/Tcf3 combination, and to determine the specific effects of Mist1, Tcf3, and
the Mist1/Tcf3 combination. This was accomplished by transfecting ParC10 cells
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and transiently expressing rat Mist1 and rat Tcf3 cDNA with rat PSP promoter or
rat PSP promoter + intron regulating luciferase.
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METHODS
AMYLASE-1 PROMOTER CLONES
Different amylase 1 (Amy1a) promoter clones were made using the PCR
amplification method. The promoter regions were determined using the ECR
Browser: Evolutionary Conservation of Genomes website,
http://ecrbrowser.dcode.org/. The rat and mouse Amy1a promoter regions were
compared on ECR. Conserved regions containing suggested activating
transcription factor binding sites were chosen. A 1000 base pair region (mAmyI 1
kb) spanning the proximal promoter, and an adjacent 2000 base pair region
(mAmyI R2) were mapped (Figure 1). These regions were cloned into an empty
pGL4.10 luciferase vector supplied by Promega. This vector produces luciferase
protein that can be used as a measure of promoter activity. Primers flanking the
mouse promoter regions of interest were designed for PCR amplification and are
listed in Table 1. The forward primer for the 1000 base pair promoter region,
termed ‘M.Amy1 1kb BglII For’, contains a BglII restriction site, and the reverse
primer for this region, ‘M.Amy1 1kb HindIII Rev’, contains a HindIII restriction site.
The forward primer for the 2000 base pair promoter region, ‘M.Amy1 XhoI R2
For’, contains a XhoI restriction site, and the reverse primer for this region,
‘M.Amy1 BglII Rev’, contains a BglII restriction site. PCR amplification of mAmyI
1kb and mAmyI R2 started with an initial denaturation of mouse genomic DNA at
95 °C for 6:00. This was followed by eight cycles of denaturation at 95 °C for
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thirty seconds, annealing at 58 °C for thirty seconds, and extension at 72 °C for
two minutes. These eight cycles were followed by twenty-five cycles of
denaturing at 95 °C for thirty seconds, then annealing at 60 °C for thirty seconds,
and extension at 72 °C for two minutes and ten seconds. The PCR products
were purified by spinning down PCR reactions onto a silica membrane using the
QIAquick PCR Purification Kit (Qiagen) according to the spin protocol. After
being purified, mAmyI 1kb PCR product and an empty pGL4.10 luciferase vector
were double digested with BglII and HindIII restriction enzymes creating fragment
ends that hybridized together during a ligation reaction. The mAmyI R2 PCR
product and an empty pGL4.10 luciferase vector were double digested with BglII
and XhoI restriction enzymes. The digested promoter fragments and pGL4.10
vectors were purified via gel extraction according to the QIAquick Gel Extraction
Kit spin protocol. After quantitating the DNA obtained from the gel extraction,
mAmyI 1kb was ligated into pGL4.10 digested with BglII and HindIII, and mAmyI
R2 was ligated into pGL4.10 digested with BglII and XhoI using T4 DNA ligase
supplied by Invitrogen. The samples were put in a PCR Thermocycler overnight
at 16 °C. The ligation reactions were transformed into TOPO 10 DH5-!
competent cells. Colonies were screened for promoter inserts using the Promega
Wizard Plus SV Minipreps DNA Purification System by lysing the cells, removing
endonucleases and other proteins released during lysis using an alkaline
protease, neutralizing the lysate, and then applying the neutralized lysate to a
spin column membrane. Once miniprep DNA was quantified, these clones were
screened by restriction enzyme digests. A double digest using enzymes BglII and
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HindIII were used to determine miniprep samples containing mAmyI 1kb inserts.
The enzyme BsaI was used to screen for the promoter fragment in the mAmyI R2
miniprep samples. Samples containing correct fragment lengths on a 1%
agarose gel were confirmed by sequencing.
These single promoter fragment clones were then combined to include
both promoter fragments in order to test if promoter expression was stronger with
the regions together. The promoter fragment, mAmyI R2, was ligated into the
mAmyI-1kb-pGL4.10 clone. First, the R2 region was amplified using the same
PCR primers listed in Table 1 for the R2 region and the same PCR conditions
listed above. After the PCR product was purified, the R2 fragment and mAmyI1kb-pGL4.10 DNA was double digested with XhoI and BglII restriction enzymes.
The mAmyI R2 fragment and mAmyI-1kb-pGL4.10 DNA was purified via gel
extraction and then ligated together with T4 DNA ligase. The mAmyI-R1R2.pGL4.10 ligation product was transformed into TOPO 10 DH5-! competent
cells. Colonies were chosen and screened for the correct promoter insert using
the Promega Wizard Plus SV Minipreps DNA Purification System. The miniprep
samples were digested with SacI enzyme to screen for a clone with the inserted
mAmyI R2 region. Samples containing the correctly digested band lengths were
confirmed by DNA sequencing.
The 1000 base pair amylase promoter sequence was analyzed for
transcriptional repressor binding sites. Promoter clones with these sites removed
were cloned into a Promega pGL4.23 luciferase vector. This vector contains a
minimal promoter to enhance the DNA region of interest expression. The two
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promoter regions were 900 base pairs and 700 base pairs in length and
designated mAmy1-900bp and mAmy1-700 bp. The forward primer used for both
was the same primer used for amplifying the 1000 base pair promoter region.
The reverse primer used for mAmy1-900bp promoter region was mAmy1 900bp
HindIII Rev that contains a HindIII restriction site. The reverse primer for mAmy1700bp promoter region was mAmy1 700bp HindIII Rev also containing a HindIII
restriction site. These three primers are listed in Table 1. The PCR conditions
used to amplify the promoter regions consisted of an initial denaturation at 95 °C
for six minutes followed by eight cycles of denaturation at 95 °C for thirty
seconds, annealing at 55 °C for thirty seconds, and extension at 72 °C for two
minutes. These cycles were followed by twenty-five additional cycles of
denaturation at 95 °C for thirty seconds, annealing at 58 °C for thirty seconds,
and extension at 72 °C for two minutes. The PCR products were purified via the
QIAquick PCR Purification Kit following included instructions. Both the 900 base
pair and 700 base pair PCR products and a pGL4.23 luciferase vector were
digested with BglII and HindIII restriction enzymes. The digested promoter
fragments and the digested pGL4.23 luciferase were gel purified using the
QIAquick Gel Extraction kit. After purification, an overnight ligation reaction using
T4 DNA ligase was performed at 16 °C in order to ligate the 900 base pair and
700 base pair promoter fragments into the pGL4.23 vector. The ligation products
were transformed into TOPO 10 DH5-! competent cells. Colonies were grown up
and screened for promoter inserts using the Promega Wizard Plus SV Minipreps
DNA Purification System. After the DNA was quantified, mAmy1-900bp promoter
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inserts were screened by a BssSI restriction digest, and mAmy1-700bp promoter
inserts were screened by a double digest using NotI and BglII restriction
enzymes. The digested DNA was analyzed via gel electrophoresis, and samples
with correct band lengths were sent to sequence at the University of Louisville
DNA sequencing core. Correct promoter sequences were confirmed and these
DNA samples were purified using the QIAfilter Plasmid Midi Prep kit. This DNA
purification is a modified alkaline lysis procedure where the neutralized lysate is
bound to a QIAGEN Anion-Exchange Resin. After the lysate is applied to the
resin, impurities such as RNA are removed by a medium-salt wash, and then an
elution with a high-salt buffer concentrates plasmid DNA. The DNA is desalted by
isopropanol precipitation.
The NUPR1 promoter region was amplified by PCR and ligated into the
pGL4.10 luciferase vector by standard cloning methods as described above.
Figure 5 depicts this promoter construct.
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Table 1: PCR primers for mouse Amylase 1 promoter clones
Clone PCR primer used
Forward:
5'-CACCAGATCTCTCAGCTTCAGCATCACATCTCTG-3'
Rev:
R1
5'-CACCAAGCTTCATGTGCTGCCTTCCACTGC-3'
Forward:
5'-CACCCTCGAGACTCCCTTGCTCCTTGACTCTCAT-3'
Reverse:
R2
5'-CACCAGATCTCATCAGTCCCTTCGTCCATTGTCA-3'
Forward:
5'-CACCAGATCTCTCAGCTTCAGCATCACATCTCTG-3'
Reverse:
700bp 5'-CACCAAGCTTTCTTGGGGGAAAAGGAGTTT-3'
Forward:
5'-CACCAGATCTCTCAGCTTCAGCATCACATCTCTG-3'
Reverse:
900bp 5'-CACCAAGCTTCTTGCATGGATATTTCACTGGT-3'
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Tm
For:
63.5°C
Rev:
66.3°C
For:
66.8°C
Rev:
64.5°C
For:
63.5°C
Rev:
62.6°C
For:
63.5°C
Rev:
62.0°C

E-BOX MUTANT PSP PROMOTER CLONES
The PSP 2000 base-pair promoter sequence and the pGL4.10 luciferase
vector sequence were analyzed for Mist1 transcription factor binding sites, or an
E-box consensus sequence binding site, 5’-CANNTG-3’ [85]. Two sites were
found in the PSP 2kb promoter region, and three sites were found in the pGL4.10
vector. Mist1 transcription factor was predicted to enhance expression of PSP. Ebox sites were mutated in a previously made clone containing the PSP 2kb
promoter region ligated into pGL4.10.
First, to eliminate any background activity from Mist1 the sites in the
pGL4.10 vector were mutated. The sites mutated in pGL4.10 were designated
site A, site B, and site C and are depicted in Figure 11. The mutagenic primers
used are listed in Table 2 below. The QuikChange II Site-Directed Mutagenesis
Kit supplied by Agilent Technologies was used to perform mutagenesis of the
Mist1 sites according to kit instructions. First site A was mutated, and then this
confirmed clone was used as a template to mutate site B resulting in a clone that
had both sites A and B mutated. Then this double Mist1 mutant clone was used
as a template for mutating Mist1 site C. The final product was pGL4.10 with Mist1
binding sites A, B, and C mutated termed, ‘Mist1mut-ABCpGL4.10’. The PCR
conditions used for all mutations were an initial denaturation of 95 °C for thirty
seconds, followed by sixteen cycles of denaturation at 95 °C for thirty seconds,
annealing at a temperature specific for the mutagenic primer used for one
minute, and extension at 68 °C for five minutes. After the PCR reaction, PCR
products were digested with DpnI enzyme. DpnI enzyme digested parental DNA
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that was not mutated during the PCR reaction. The digested product was
transformed into TOPO 10 DH5!-T1 competent cells and plated on ampicillin
agar plates. Colonies were chosen, inoculated in LB broth, and grown in order to
screen them for correct mutations. The Promega Wizard Plus SV Minipreps DNA
Purification System was used to extract DNA from the bacterial cells, the DNA
was quantified, and then sent for sequencing. Confirmed sequences with
correctly mutated binding sites were purified using the QIAfilter Plasmid Midi
Prep Kit via kit instructions.
The next step was to ligate the PSP 2kb promoter region into the mutated
pGL4.10 vector. The PSP 2kb promoter clone previously made in the laboratory,
-1980PSPprom.pGL4.10, and the mutated pGL4.10 was digested with KpnI and
XhoI restriction enzymes. The digested fragment and vector were gel purified
using the QIAquick Gel Extraction kit. The purified PSP 2kb promoter was ligated
into the purified, mutated pGL4.10 using T4 DNA ligase at 16 °C overnight. The
ligation product was transformed into TOPO 10 DH5-! competent cells. Colonies
were inoculated and screened for the promoter insert using the Promega Wizard
Plus SV Minipreps DNA Purification System followed by XhoI digest to screen for
the correct insert. Samples containing correctly digested band lengths were sent
to sequence. The correct sequence was confirmed and the plasmid clone purified
using the QIAfilter Plasmid Midi Prep Kit.
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Table 2: Mutagenesis primers for Mist1 mutant pGL4.10 and rat PSP 2kb
promoter clones.
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PSP PROMOTER + INTRON CLONES
The PSP 2kb promoter clone and the E-box mutant PSP 2kb promoter
clones were repressed by Mist1 transcription factor. Therefore, additional sites in
the PSP gene by which Mist1 could activate transcription were sought. There is
evidence that Mist1 binds E-box sequences within the first intron of genes, such
as the ubiquitin ligase Mindbomb1, Mib1, gene [48]. The intron regions of the
PSP gene were analyzed for Mist1 E-box binding sites, and sites were found
within the second, third, and fifth introns. PCR primers were made for the regions
between the second and fourth exons and between the second and sixth exons,
but the region between the second and fourth exons was the only region
successfully amplified. This region will be referred to as the PSP intron region.
The PCR primers used to clone the intron region were: the forward primer with a
SalI restriction site, PSPex2SalI For B: 5’ –CAA CTT GTC GAC CTT GTG GTC
TTG TGT GGC-3'; the reverse primer with a SalI restriction site, PSPex4SalI
Rev: 5'-CAT TGG TCG ACA GCC CAG CTT GAA GAT CC-3'. The PCR
conditions used to amplify the PSP intron region consisted of an initial
denaturation at 95 °C for six minutes, followed by eight cycles of denaturation at
95 °C for thirty seconds, annealing at 61 °C for thirty seconds, and extension at
72 °C for two minutes and twenty seconds. After these eight cycles, the reaction
underwent twenty-five more cycles of denaturation at 95 °C for thirty seconds,
annealing at 63 °C for thirty seconds, and extension at 72 °C for two minutes and
thirty seconds. Then the amplified intron region was PCR purified using the
QIAquick PCR Purification Kit following the kit instructions.
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The next step was to insert the amplified intron region into the PSP 1.5 kb
promoter construct made previously in the laboratory. The PSP 1.5 kb promoter
was digested with XhoI restriction enzyme and the PSP intron region was
digested with SalI restriction enzyme. The XhoI digested promoter was purified
via ethanol precipitation and then digested with calf intestinal phosphatase (CIP)
enzyme in order to remove phosphate groups to prevent the XhoI cut vector from
re-ligating to itself in the ligation step. After CIP digestion, the PSP 1.5 kb
promoter was PCR purified. While the PSP 1.5 kb promoter was undergoing the
various digestions, the PSP intron region was gel purified using the QIAquick Gel
Extraction Kit. The purified PSP 1.5 kb promoter and the purified PSP intron
region were ligated together and incubated overnight at 16 °C. The ligation
reaction was transformed into TOPO 10 DH5-! competent cells and plated on LB
plates containing ampicillin. Colonies were inoculated the next day and prepped
for screening the PSP intron region using the Promega Wizard Plus SV
Minipreps DNA Purification System. Miniprep samples were digested with NheI
enzyme to screen for the PSP intron insert in the PSP 1.5 kb promoter. Samples
with correctly digested band lengths were sent to the DNAcore for sequencing.
After the correct sequence was confirmed, the PSP promoter + intron sample
was purified using the QIAfilter Midi Prep Kit.

TRANSFECTIONS
Transfections allow testing of exogenous, functional DNA by introducing
the DNA of interest into a mammalian cell type. A cationic lipid reagent is added
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to a reaction containing the DNA of interest. The positive charge of the cationic
lipid interacts with the negatively charged DNA backbone, and the positive
charge of the lipids allows the DNA-lipid complex to cross the negatively
charged, hydrophobic cell membrane [101]. The promoter activity of the amylase1, NUPR1, PSP promoter (non-mutant and mutant), and PSP promoter + intron
clones were tested by transfecting each DNA into mammalian cell lines. Each
promoter had been cloned adjacent to the luciferase coding sequence, such that
activation of the promoter stimulates luciferase enzyme expression, which is
easily measured.
Amylase-1 was transfected into ParC5, 3T3-L1, and JEG-3 cell lines.
ParC5 cell type is an immortalized rat parotid acinar cell line, 3T3-L1 cell type is
a mouse embryonic fibroblast cell line, and JEG-3 cell type is a human
choriocarcinoma cell line [102-104]. The NUPR1 promoter was tested in ParC10
and 3T3-L1 cell types. ParC10 cell line is a slightly different immortalized rat
parotid acinar cell line than ParC5. The transfection reagent used for amylase-1
promoter and NUPR1 promoter experiments was lipofectamine. The optimized
amylase-1 promoter transfection conditions for ParC5 cells, 3T3-L1 cells, and
JEG-3 cells were as follows: cells were split into a six-well plate at 100,000 cells
per well; the total DNA used for experiments testing amylase-1 promoter activity
was 1500 ng; the DNA:lipofectamine ratio for was 2:3. The optimized NUPR1
promoter transfection conditions for ParC10 cells were 250,000 cells per well in a
six-well plate, 640 ng of total DNA was transfected, and the DNA:lipofectamine
ratio was 1:8. The optimized conditions for 3T3-L1 cells were 100,000 cells per
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well were plated in a six-well plate, 800 ng of total DNA was transfected, and the
DNA:lipofectamine ratio was 1:4. Renilla luciferase was transfected at the same
concentration in the amylase-1 promoter and NUPR1 promoter experiments and
used as a measure of transfection efficiency.
The PSP 2kb promoter (non-mutants and E-box mutants) and PSP
promoter + intron DNA clones were tested in ParC10 cells, another immortalized
rat parotid acinar cell line [105]. The transfection reagent used for experiments
testing PSP 2kb promoter (non-mutant and E-box mutant) was FugeneHD. The
optimized transfection conditions for these experiments were cells were plated at
60,000 cells per well in a 24-well plate, the total DNA concentration transfected
was 200 ng, and the DNA:FugeneHD ratio used was 1:8. Renilla was used as
the measure of transfection efficiency in experiments testing E-box mutant PSP 2
kb promoter activity until the renilla activity was repressed. Cypridina luciferase
was tested as the measure of transfection efficiency, and Mist1 did not repress
the values measuring Cypridina. Cypridina was then used in the remaining E-box
mutant PSP 2kb promoter experiments and in all experiments testing PSP
promoter + intron activity.

FIREFLY LUCIFERASE, RENILLA LUCIFERASE, AND CYPRIDINA
LUCIFERASE ASSAYS
All the promoter constructs used in the transient transfection assays were
ligated into a vector containing the luciferase gene. The amount of luciferase
protein synthesized is a measure of promoter expression [106]. After the
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transfected cells were allowed to grow for 48 hours, the media was removed and
passive lysis buffer was applied to each well. The lysates from each well were
tested for promoter activity by performing luciferase assays. The firefly luciferase
substrate was injected into each individual sample and the relative light units
(RLU) were measured by a luminometer. Renilla luciferase substrate and
cypridina luciferase substrates were injected into another set of the same
samples to test transfection efficiency. The final promoter activity was measured
as the ratio of firefly luciferase RLU values:renilla luciferase or cypridina
luciferase RLU values.
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RESULTS
CHARACTERIZING THE PROXIMAL PROMOTER OF THE AMYLASE I GENE
Alpha-amylase (Amy-1) is an important and abundant protein in saliva that
helps digest starch to maltose and glucose [33]. The Amy-1 gene is highly
expressed in fully differentiated parotid acinar cells [30]. Schibler et. al.
determined and showed activation of the amylase 1 promoter region years ago
[28]. Since then there has been little investigation into characterizing the Amy-1
promoter region even though the protein is a major component in saliva. Recent
experiments performed in the laboratory have found this region to be inactive,
contradicting Schibler’s results. The goal of studying the Amy-1 promoter was to
determine active regions upstream of the transcription start site. Determining the
active promoter will allow future work to define transcriptional activator sites
within this region. Previously, a colleague in the laboratory performed
transfections in ParC5 cells testing the activity of the rat amylase I R2-R1
promoter construct. The results from luciferase and renilla assays show this
promoter region is less active than the negative control, pGL4.10; therefore, the
promoter is inactive (Figure 4). Since the amylase I gene between the rat and
mouse is conserved, mouse amylase I clones were made to test promoter
expression.
The amylase I promoter clones used in this work are listed in Table 1 and
Figure 3. A 1,000 bp promoter region (R1) directly upstream of the transcription
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start site was ligated into a pGL4.10 luciferase. The levels of promoter activity
are determined by measuring luciferase expression. A 2,000 bp promoter region
(R2) directly upstream of the 1,000 bp region was ligated into the R1 amylase I
promoter clone.
To test amylase I promoter activity, the mouse R1 and mouse R2-R1
clones were transfected in ParC5, 3T3-L1, and JEG-3 cell lines. The harvested
cell lysates were measured for promoter activity by luciferase assays and the
transfection efficiency was measured by renilla luciferase assays. Promoter
activity was determined by normalizing average luciferase values to average
renilla luciferase values. As shown in Figure 5, mouse amylase I R1 promoter
and mouse amylase R2-R1 promoter activity is less than the negative and
positive controls. These results were demonstrated in three different cell lines
confirming the amylase promoter regions tested were repressed. After seeing the
repressed promoter activity, sequence analysis was done and identified multiple
transcriptional repressor sites in the R1 region.
Amylase promoter clones with the repressor sites removed were made for
both the mouse and rat. A 900 bp promoter clone eliminated GFI1, ZEB1, and
FREAC4 transcription factor binding sites. A 700 bp promoter clone eliminated
GFI1, ZEB1, FREAC4, and two CHOP transcription factor binding sites (Figure
3). Both promoter clones with these sites removed were ligated into the minimal
promoter pGL4.23 luciferase vector. The sequences of each promoter clone
were confirmed. The purified amylase I promoter clones were transfected in
ParC5, 3T3-L1, and JEG-3 cell lines to test promoter activity. Data obtained from
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luciferase and renilla assays show amylase promoter activity is still repressed
compared to the promoterless negative control, pGL4.23, in each cell line tested
(Figure 6). These data indicate that the regulatory region of amylase I gene are
outside the 3,000 bp region tested. Initial work with the parotid amylase promoter
looked at its endogenous expression and found the promoter to be inactive. Even
though an unpublished observation found a 300 bp amylase promoter to be
active, this small promoter region would not benefit the goal of identifying active
sites. The data agree with the literature that the mouse amylase promoter
constructs tested were not active in different cell types.
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Figure 3: Amylase I Promoter Clones
FREAC4
ZEB1

CHOP

CHOP

GFI1

Parotid
Exon 1a

R2

R1

Luciferase

R1

Luciferase
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Exon 1b

Figure 3: A diagram of the amylase I promoter regions used in transfection
experiments. The transcription start sites for the parotid and liver are shown. The
constructs for the 1kb promoter, represented here as R1, and the 2kb promoter
region added to the 1kb promoter clone, represented here as R2, are shown
ligated to the pGL4.10 luciferase vector. The transcriptional repressor binding
sites are indicated in the R1 promoter region.
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Figure 4: Rat Amylase promoter activity in ParC5 cells
1800

(Luciferase/Renilla)*1000

1600
1400
1200
1000

pGL4.10
rPSP500bp

800

rAmy-R2-R1

600
400
200
0
pGL4.10

rPSP500bp

rAmy-R2-R1

Figure 4: Testing the activity of rat amylase R2-R1 promoter. The activity of rat
amylase I promoter is compared to a negative control, pGL4.10, and a positive
control rat PSP 500 bp promoter. The rat amylase promoter has lower activity
compared to the negative and positive controls. N = 1 independent experiment
done with triplicate wells.
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Figure 5: Mouse amylase I promoter activity in different cell lines.
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Figure 5: Testing the activity of mouse amylase R1 and mouse amylase R2-R1
promoter. The activity of mouse amylase I promoter is compared to a
promoterless negative control, pGL4.10, and a positive control rat PSP 500 bp
promoter. Each cell line demonstrates low activity of the amylase I promoters.
For each cell type, N = 1 independent experiment with triplicate wells.
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Figure 6: Activity of mouse and rat amylase I promoter with repressors
removed in different cell lines.
900

(Luciferase/Renilla)*1000

800
700
600

pGL4.23

500

mAmy700bp

400

mAmy900bp
rAmy700bp

300

rAmy900bp

200
100
0
Par C5

3T3-L1

JEG-3

Figure 6: Testing the activity of mouse amylase 900 bp promoter and mouse
amylase 700 bp promoter. The activity of mouse amylase I promoter is compared
to a negative control, pGL4.23. The activity of the amylase I promoters is still
very low when transcriptional repressor binding sites are removed in three
different cell lines. For each cell type, N = 1 independent experiment with
triplicate wells.
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CHARACTERIZING THE NUPR1 PROMOTER REGION
The next goal was to characterize the NUPR1 promoter by testing the
predicted regulatory interactions of this gene. The NUPR1 promoter clone used
in the following experiments contains a 1305 bp proximal promoter region
directing expression of luciferase (Figure 7). Cited2 + p300 and IRF2 + PCAF
were predicted to stimulate gene expression based on the hypothetical network
described above (Figure 2). The NUPR1 promoter clone was co-transfected with
Cited2 + p300 into ParC10 and 3T3-L1 cell lines. The promoter was also cotransfected with IRF2 + PCAF in 3T3-L1 cells. Luciferase and renilla assays were
performed to test promoter activity. NUPR1 promoter activity was determined by
normalizing luciferase to renilla.
The NUPR1 promoter was not active in the ParC10 cell line (Figure 8A).
The promoter activity was only a little higher than the promoterless pGL4.10
negative control, but not high enough to confirm its activity in ParC10 cells. Even
though the promoter was inactive, it was analyzed using ANOVA and no
significant change in NUPR1 promoter activity was found when Cited2 + p300
cDNAs were co-transfected in ParC10 cells (p = 0.0961).
The NUPR1 promoter was active when transfected in the 3T3-L1 cell line.
A one-tailed T-test calculated a significant increase in promoter activity when
comparing the promoterless pGL4.10 negative control to the NUPR1 promoter, p
= 0.05. A one-tailed T-test determined no significant change in NUPR1 promoter
activity when Cited2 + p300 were co-transfected, p = 0.2058 (Figure 8B).

&'"

The second interaction tested was the effect of IRF2 + PCAF transcription
factors on NUPR1 promoter activity. Again, the NUPR1 promoter exhibited
higher activity than the promoterless pGL4.10 negative control in 3T3-L1 cells
(Figure 9). However, the ANOVA calculated a non-significant change in NUPR1
promoter activity when IRF2 + PCAF are co-transfected in 3T3-L1 cells, p =
0.1409. The conclusion from this data is the NUPR1 promoter is not being
activated by either Cited2 + p300 or IRF2 + PCAF in two different cell lines;
therefore, the data do not support the hypothetical transcription factor network.
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Figure 7: NUPR1 promoter clone
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Figure 7: A picture representing the NUPR1 gene and promoter region. The
transcription start site and the three exons of the NUPR1 gene are shown. The
1305 bp promoter was ligated into the pGL4.10 luciferase vector.
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Figure 8: Effect of Cited2 + p300 on NUPR1 promoter activity in ParC10 and
Effect of Cited2 + p300 on NUPR1 promoter activity in ParC10 cells

3T3-L1 cell lines.
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B. 3T3-L1 cells
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Figure 8: A: The NUPR1 promoter clone was co-transfected with Cited2 + p300
expression plasmids into ParC10 cells. Promoter activity was determined by
normalizing raw luciferase to raw renilla luciferase values. ANOVA did not show
any significant changes between any of the groups, p = 0.0961. Therefore,
Cited2 + p300 do not activate NUPR1 promoter in ParC10 cells. The pGL4.10
control was set to 100%. N = 4 independent experiments done with triplicate
wells. B: The NUPR1 promoter clone alone was activated in 3T3-L1 cells and a
Mann-Whitney one-tailed t-test calculated a significant activation, p = 0.05. The
NUPR1 promoter clone was co-transfected with Cited2 + p300. One-tailed T-test
of NUPR1 calculated a p-value that is not significant. This statistical analysis
proves NUPR1 promoter is not activated by Cited2 + p300 in 3T3-L1 cells. The
pGL4.10 control was set to 100%. N = 3 independent experiments done with
triplicate wells.
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Effect of IRF2 + PCAF on NUPR1
promoter activity in 3T3-L1 cells
Figure 9: Effect of IRF2 + PCAF on NUPR1 promoter activity in 3T3-L1 cells.
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Figure 9: The NUPR1 promoter-luciferase clone was co-transfected with IRF2 +
PCAF cDNAs in 3T3-L1 cells. Promoter activity was determined by normalizing
raw luciferase to raw renilla luciferase values. ANOVA did not show any
significant changes between any of the groups, p = 0.1409. Therefore, IRF2 +
PCAF do not activate NUPR1 promoter in 3T3-L1 cells. The pGL4.10 control was
set to 100%. N = 2 independent experiments done with triplicate wells.
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CHARACTERIZING PSP PROMOTER REGION
Parotid secretory protein (PSP) is an abundant protein in saliva and has
been suggested to have antibacterial properties that protect the oral cavity.
Research has focused on PSP protein function, but much work remains to be
done to characterize PSP gene regulation. The PSP gene is a marker of parotid
differentiation and contains regulatory regions in its promoter region that need to
be characterized. One transcription factor that was identified in the hypothetical
transcription factor network was Mist1, and it was predicted to act on PSP
(Figure 2). Mist1 is a transcriptional activator that binds the E-box motif
CANNTG, and these sites were identified in the rat PSP promoter region. The
first goal was to determine if Mist1 activates the rat PSP 2 kb promoter region.
The second goal was to determine if mutating E-box DNA binding sites in the rat
PSP 2kb promoter would prevent activation.
The rat PSP promoter clones, non-mutated and mutated, are depicted in
Figure 10 and Figure 11. The non-mutated PSP promoter clone was previously
made in the laboratory and contains a 2,000 bp proximal promoter region next to
the transcription start site of the PSP gene. The region was PCR amplified and
then ligated into a pGL4.10 luciferase vector. The correct sequence was
confirmed, the DNA was purified, and transfection experiments were performed
to test promoter activity.
In addition, sequence analysis found E-box sites, or Mist1 binding sites, in
the pGL4.10 luciferase vector and in the 2,000 bp promoter region (Figure 11).
These sites were mutated following the recommended protocol in the
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QuikChange II Site-directed Mutagenesis Kit provided by Stratagene. The correct
sequence was confirmed, the DNA was purified, and transfection experiments
were performed to test promoter activity. The non-mutated and mutated promoter
DNA clones were co-transfected with rat Mist1 cDNA in ParC10 cells. The cell
lysates were tested for promoter activity and transfection efficiency by luciferase
assays and renilla luciferase assays, respectively.
The data show that the non-mutated PSP 2kb promoter and the mutant
clones, PSP2kb-pGL4.10$M and PSP2kb$M-pGL4.10$M, were active in ParC10
cells (Figures 10 and 11). Samples co-transfected with Mist1 had repressed
activity (Figure 12). The promoter activity was repressed by at least one-half or
more when Mist1 was co-transfected as compared to the promoter activity
without Mist1 co-transfected. Two-tailed T-test calculated nonsignificant
repression for PSP2kb-pGL4.10$M (p = 0.1230) and significant repression for
PSP2kb$M-pGL4.10$M (p = 0.0132). The two-tailed T-test for the non-mutated
PSP 2kb promoter did not calculate a significant repression (p = 0.0822), but
promoter activity appears to decrease by about one-half when Mist1 is cotransfected as compared to the control PSP 2kb promoter. Based on these
results, Mist1 alone does not activate the PSP gene through the promoter region;
therefore, this does not support the hypothetical network of Mist1 activating PSP
through the promoter region.
Mist1 can activate gene expression by binding as a heterodimer with
another bHLH protein. Tcf3, or E2A, has been shown to bind DNA as a
heterodimer with Mist1 and bind E-box sites [84]. The first goal was to
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demonstrate that a combination of Mist1/Tcf3 transcription factors did not
activate the PSP promoter. This goal was achieved by co-transfecting a
combination of rat Mist1 cDNA and rat Tcf3 cDNA with the rat PSP 1.5 kb
promoter construct (Figure 10) in the ParC10 cell line. The results from this data
observe no change in promoter activity (Figure 14). A one-tailed T-test calculated
a p-value of 0.1735, indicating there was no effect of the Mist1/Tcf3 transcription
factor combination. This result supported the hypothesis that the combination of
Mist1 and Tcf3 transcription factors does not activate the PSP promoter region.

'%"

Figure 10: rat PSP gene with indicated promoter clone constructs.

Figure 10: A diagram of the PSP gene. Exons 1 – 4 are labeled and the red
arrow indicates the transcription start site. The PSP 1,500 bp promoter and the
PSP 2,000 bp promoter constructs are shown ligated to a pGL4.10 luciferase
vector. The PSP 2,000 bp promoter clone was used in co-transfection
experiments with Mist1 transcription factor.
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Figure 11: rat PSP 2kb promoter construct with E-box binding sites for
mutagenesis.
A. PSP2kb-pGL4.10!M

B. PSP2kb!M-pGL4.10!M

Figure 11: A diagram of the PSP 2kb promoter ligated in pGL4.10 luciferase
vector. The consensus E-box DNA site mutated in these clones is CANNTG.
Sites A,B, and C are located in pGL4.10 and sites 3 and 4 are located in PSP
2kb promoter. A: The PSP2kb-pGL4.10$M clone has E-box sites A, B, and C
mutated in the pGL4.10 luciferase vector, and the PSP 2kb promoter fragment is
ligated to this mutated vector. B: The PSP2kb$M-pGL4.10$M clone has E-box
sites A, B, and C mutated in the pGL4.10 luciferase vector, and E-box sites 3 and
4 are mutated in the PSP 2kb promoter region.

''"

Figure 12: Testing the effect of Mist1 on non-mutant and E-box mutant PSP
promoter.
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Figure 12: Non-mutated PSP promoter and E-box mutated PSP promoter
activity by Mist1. Promoter activity is measured by the percent
luciferase:cypridina ratio and compared to non-mutated PSP promoter activity
(set to 100%). ANOVA found significant changes in the data (p = 0.0205), so twotailed paired T-tests were performed to distinguish changes in promoter activity
when Mist1 was co-transfected. N = 2 independent experiments done with
triplicate wells.
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CHARACTERIZATION OF PSP PROMOTER + INTRON REGION
Mist1 did not activate the PSP proximal promoter, so I investigated
another way this gene may be activated by Mist1. Mist1 has been shown to
activate gene expression by binding to E-box sites in the first intron of genes [48].
The next goal was to determine if a combination of Mist1/Tcf3 transcription
factors activate PSP through intron regions of the gene. Sequence analysis of
the rat PSP gene, exons and introns, found E-box binding sites in the second,
third, and fifth introns (Figure 13). The region between exon 2 and exon 4 was
successfully PCR amplified. This region contains E-boxes in the second and third
introns. Amplifying the region containing E-box sites in the fifth intron was
unsuccessful, so attempts to make this clone were halted. The intronic amplified
region was digested with SalI restriction enzyme, and the PSP 1.5 kb promoter
clone was digested with XhoI restriction enzyme. When the intronic region was
ligated into the PSP 1.5kb promoter clone, the SalI sites and the XhoI sites at the
cloning region were abolished. The only issue with cloning with these enzymes
was the risk that the intronic region would be ligated in the opposite orientation;
however, DNA sequence analysis confirmed a clone that contained the inserted
region in the correct, or forward, orientation. After sequence confirmation, this
clone was purified and used in transfection experiments.
A combination of rat Mist1 cDNA and rat Tcf3 cDNA was co-transfected
with the PSP promoter + intron clone into ParC10 cells. This experiment was
done simultaneously when testing the effect of Mist1 and Tcf3 on the PSP 1.5 kb
promoter. Performing these experiments in unison resulted in the PSP 1.5 kb
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promoter to be used as a good negative control to compare to the PSP promoter
+ intron results. The results from testing the effect of the transcription factor
combination determined that PSP promoter + intron activity is increased by about
2-fold (Figure 14). A one-tailed T-test calculated a significant change in PSP
promoter + intron activity when Mist1/Tcf3 was co-transfected, p = 0.0136. These
results conclude that PSP can be activated through the second and third intron
regions by a combination of Mist1/Tcf3. This conclusion supports the hypothesis
that a Mist1/Tcf3 combination can activate PSP through intronic binding sites.
The next goal was to determine if there is a specific effect from Mist1
alone or Tcf3 alone. ParC10 cells were transfected with PSP 1.5 kb promoter or
PSP promoter + intron and Mist1 alone, Tcf3 alone, or a Mist1/Tcf3 combination.
Luciferase assay RLU values were normalized to Cypridina RLU values to
determine promoter activity. ANOVA of PSP 1.5 kb promoter group was
significant, p = 0.0001 (Figure 15). Mann Whitney two-tailed T-test comparing the
control, PSP 1.5 kb alone, to the different experimental groups was performed.
There was no change in promoter activity by Tcf3 when compared to the
negative control, promoter alone, and the T-test calculated the effect of Tcf3
alone was not significant, p = 0.3429. Mist1 repressed promoter activity, and this
repressive effect of Mist1 was significant, p = 0.0286. The combination of
Mist1/Tcf3 repressed the promoter as well, and the repression by Mist1/Tcf3 was
significant as calculated by the T-test, p = 0.0286. As observed above, the effect
of Mist1 and the combination of Mist1/Tcf3 repressed transcription from the PSP
1.5 kb promoter, and transfection of Mist1 alone is sufficient for repression.
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A Mann-Whitney test using a two-tailed T-test was used to test
significance between the control group, PSP promoter + intron without Mist1,
Tcf3, or the combination, and the experimental groups. The effect by Tcf3 alone
appeared to increase luciferase activity, but the Mann-Whitney test calculated a
non-significant p-value for the effect of Tcf3 on PSP promoter + intron (p =
0.3429). Mist1 did not change PSP promoter + intron activity, and the MannWhitney test calculated p > 0.9999 for the effect of Mist1 on PSP promoter +
intron. However, PSP promoter + intron co-transfected with the combination of
Mist1/Tcf3 exhibited a dramatic increase in activity, and had a significant p-value
from the Mann-Whitney two-tailed T-test, p = 0.0286 (Figure 15). Based on this
data there is not a specific effect from Mist1 alone or Tcf3 alone on PSP
promoter + intron activity. This data further confirms results that a combination of
Mist1 and Tcf3 activates PSP through the second and third intron regions. The
data support the hypothetical network that Mist1 does interact with PSP. The
novelty of this interaction is that Mist1 activates PSP when the E-box protein Tcf3
is present, and activation by Mist1 can be through the intron regions of the PSP
gene.
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Figure 13: PSP promoter + intron clone
CAGCTG

CAGCTG

TSS
Exon 1

PSP 1.5 kb

Exon 2

PSP intron

Exon 3

Exon 4

Luciferase

Figure 13: The top of the figure shows the first four exons (labeled 1 - 4
underneath) and the first three intron regions of the PSP gene. The E-box
binding sites in the intronic regions are labeled. The bottom of the figure is the
PSP promoter + intron clone used in transfection experiments. The dotted lines
indicate the PSP intron region that was amplified from rat genomic DNA. The
intronic region was ligated into the PSP 1.5 kb promoter clone depicted in figure
10.
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Figure 14: Testing the effect of Mist1/Tcf3 combination on PSP promoter
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and PSP promoter + intron activity.
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Figure 14: A: PSP 1.5 kb promoter activity without and with Mist1/Tcf3 cotransfected in ParC10 cells. Promoter activity was measured as the percentage
of luciferase/cypridina. The promoter alone was set at 100 and compared to the
promoter co-transfected with the Mist1/Tcf3 combination. There was no change
in promoter activity from the Mist1/Tcf3 combination and, a one-tailed T-test
calculated an insignificant change in promoter activity, p = 0.1735. B: PSP
promoter + intron without and with a Mist1/Tcf3 combination co-transfected in
ParC10 cells. Promoter + intron activity was measured as the percentage of
luciferase/Cypridina. The PSP promoter + intron alone was set to 100 and
compared to the promoter + intron co-transfected with a Mist1/Tcf3 combination.
The promoter + intron activity increased almost two-fold, and a one-tailed T-test
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calculated a significant change in activity, p = 0.0136. N = 7 independent
experiments done with triplicate wells for both A and B.
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Figure 15: Testing the specific effect of Tcf3 alone or Mist1 alone on PSP
promoter + intron activity.
A.

B.

Luciferase/Cypridina (%)

550
550

550
550

500
500

500
500

450
450

450
450

400
400

400
400

350
350

350
350

300
300

300
300

250
250

250
250

200
200

200
200

150
150

150
150

100
100

100
100

50
50

50
50

00

p = 0.0286

Mean and Standard Error

O

--

P
Q
PSP
1.5 kb promoter

+ Tcf3

+ Mist1

00

R

p > 0.9999

p = 0.3429

S O

Column

+ Mist1/Tcf3

Mean and Standard Error

--

P
U Q
PSP Tpromoter
+ intron

+ Tcf3

+ Mist1

V R

S
Column

+ Mist1/Tcf3

Figure 15: A: PSP 1.5 kb promoter activity without any transcription factor and
with Tcf3 alone, Mist1 alone, or a Mist1/Tcf3 combination. The control group,
promoter alone, was set to 100 and each experimental group was compared to
this control. ANOVA calculated significant changes among the group, p = 0.0001.
Mann-Whitney two-tailed T-test was calculated between the control and
individual experimental groups. Tcf3 did not have an effect on the promoter, p =
0.3429. Mist1 alone and the Mist1/Tcf3 combination had significant repressive
effects on the promoter, p = 0.0286 for both. B: PSP promoter + intron activity
without any transcription factor and with Tcf3 alone, Mist1 alone, or a Mist1/Tcf3
combination. The control group, promoter + intron alone, was set to 100 and
each experimental group was compared to this control. A Mann-Whitney twotailed T-test calculated a significant change when a combination of Mist1/Tcf3 is
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co-transfected with PSP promoter + intron, p = 0.0286. N = 4 independent
experiments done with triplicate wells for both A and B.
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DISCUSSION
MOUSE AMYLASE 1 PROMOTER IS INACTIVE IN DIFFERENT CELL TYPES
Salivary amylase is an abundant enzyme produced primarily from serous
cells of the parotid that hydrolyzes food starch into maltose and glucose [32, 33].
Salivary amylase affects oral biofilms and is a component of the acquired enamel
pellicle (AEP) [34, 36, 37]. Amylase has two genes located on mouse
chromosome three [25, 26]. The first locus corresponds to Amy-1, which is
expressed in the salivary gland, and the second locus is Amy-2, which is
expressed in the pancreas. The Amy-1 gene is expressed as two different mRNA
products with one in the parotid gland and the other in the liver. Amy-1 has two
promoters with tissue specific expression in the parotid gland and in the liver [28].
Testing endogenous promoter activity and measuring amylase mRNA levels
determined the location of the parotid and liver promoters and their activity [26,
28, 31].
Stable and transient transfection experiments performed in cell lines
lacking endogenous Amy-1 observed that the PL was active in all cell types, but
that the PP did not show activation in any of the cell types tested [28]. In an
isolated comment about unpublished data it was claimed that deletion of the 5’
flanking region of PP observed that removing nucleotides upstream of position 300 relieved transcriptional repression.
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The amylase parotid promoter region was determined by analysis of the
mRNA start sites, but little work has been done to characterize this region. The
lack of research defining the regulatory regions of amylase is surprising because
amylase is one of the major proteins in saliva and is a terminal differentiation
marker of the parotid gland [30]. The goal of this research was to determine
transcriptionally active promoter regions. Clones were made and tested in
transient transfection, which experiments contained up to 3 kbp of the amylase
parotid-specific promoter. Two clones were made and tested that had
transcriptional repressor binding sites removed from the 5’ end of the 1kb
proximal promoter region. Each amylase promoter clone was transfected in three
different cell lines, ParC5, 3T3-L1, and JEG-3.
All amylase parotid promoter clones were repressed compared to the
promoterless negative control, pGL4.10, in each cell line. The repression of the
1kb proximal promoter was expected because Schibler et. al. observed the same
result. The idea that activating elements could be further upstream from a
proximal promoter led to cloning an additional 2kbp region upstream of the
proximal promoter. Again, adding this 2kbp promoter region did not activate
amylase in any cell type this clone was transfected in. The results from testing
the 900 bp and 700 bp promoter clones also exhibited repression in all cell types.
This was unusual because removing transcriptional repressor sites from the
region should relieve any repressive effects. The amylase promoter was
repressed in multiple cell types even after testing a region upstream of the
suggested proximal promoter region and by removing transcriptional repressors.
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The conclusion from these amylase 1 experiments is that amylase is being
activated by another region outside of the 3 kb region tested or cryptic repressor
binding sites are present within the smallest (700 bp) promoter tested. Future
work cloning even further upstream regions might find an active promoter. Once
an active region is found analysis can be performed to characterize and define
transcriptional activators involved in amylase 1 activation.

CONFIRMING TRANSCRIPTIONAL PATHWAYS IN THE HYPOTHETICAL
TRANSCRIPTION FACTOR NETWORK OF PAROTID GLAND
DIFFERENTIATION
Many molecular mechanisms are involved in parotid gland differentiation,
and the role of transcription factors was of interest in this research. Rat parotid
gland mRNA was analyzed in the laboratory by Dr. Srirangapatnam, and the
results showed that many transcription factors are tightly regulated during parotid
gland differentiation. Testing mRNA from embryonic stages to postnatal stages
determined that a single transcription factor could be expressed at variable levels
throughout development. It appeared that related transcription factors were
expressed at the same time point, and this allowed us to determine four distinct
stages of differentiation. Each stage was examined to find transcription factors
that had increased levels of expression as genes of interest increased
expression levels. Once these patterns of expression were determined, the
transcription factors and genes were entered into the IPA program to model
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predicted interactions [24]. A hypothetical transcription factor network of parotid
gland differentiation was created using IPA (Figure 2).
The focus of the next part of my research was to validate some of the
pathways of the hypothetical transcription factor network. One of the interactions
tested was the effect of a combination of Cited2 and p300 co-factors and a
combination of IRF2 transcription factor and PCAF co-factor on NUPR1 promoter
activity. The other interaction tested was the effect of Mist1 transcription factor on
PSP promoter activity. The goal was to confirm interactions by performing
transient transfection experiments in parotid acinar cell types. Confirming
interactions would also aid in characterizing the promoter regions of interest.

NUPR1 PROXIMAL PROMOTER IS NOT ACTIVATED BY CITED2/P300 OR
IRF2/PCAF COMBINATIONS
The NUPR1 protein is a transcription factor that binds to DNA to regulate
gene expression in the exocrine cells of various tissues such as the salivary
glands, stomach, colon, liver, and kidneys [38-40]. NUPR1 was the first promoter
tested from the hypothetical network. The goal was to validate two separate
interactions with the NUPR1 promoter. These interactions included determining
the effect of the combination of Cited2 and p300 co-factors and the combination
of IRF2 and PCAF on NUPR1 promoter activity. The hypothesis tested was that
Cited2/p300 and IRF2/PCAF would activate the NUPR1 promoter. Confirming
these transcription factor interactions would support the hypothetical transcription
factor network of parotid differentiation.
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The first combination of co-factors tested to determine their effect on the
NUPR1 promoter was Cited2 and p300. Cited2 belongs to a family of genes
known as CITED (CBP/p300 interacting transactivators with ED-rich termini) [49,
50]. CITED proteins do not bind DNA, but serve as transcriptional co-activators.
Cellular Cited2 binds tightly to the CBP/p300 transcription complex, and this
interaction is predicted in the hypothetical network (Figure 6). The nuclear
phosphoprotein, p300, is widely expressed and homologous to the cAMP
response element binding protein (CBP), [54, 55]. p300 is a co-activator that links
DNA-bound transcriptional activators to the basal transcription machinery. It has
histone acetyltransferase (HAT) activity that is involved in modifying chromatin
structure within gene promoters, and the HAT activity allows p300 to increase
DNA binding efficiency of p300-interacting transcription factors [56, 57]. Both of
these histone-modifying actions result in more efficient transcription of target
genes.
The effect of Cited2 and p300 on NUPR1 promoter was tested in two
different cell lines. First, Cited2 and p300 were co-transfected with the NUPR1
promoter in ParC10 cells. The NUPR1 promoter alone was inactive in this cell
line, so the effect of Cited2 and p300 could not be determined. The ParC10 cell
line is an undifferentiated acinar cell type, so important regulators of NUPR1
gene expression might not be present [102]. After determining the NUPR1
promoter was inactive in ParC10 cells, Cited2 and p300 were co-expressed with
the NUPR1 promoter in an alternative cell line, 3T3-L1. The NUPR1 promoter
alone was active in the 3T3-L1 cell line, so all future experiments testing NUPR1
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promoter activity used these cells. Even though the promoter was active as
compared to the promoterless negative control, pGL4.10, there was no effect of
Cited2 and p300 on NUPR1 promoter activity. An example from the literature of
Cited2 repressing gene expression is on the NF-%B gene [107]. One of the ways
it represses NF-%B is by sequestering p300 and inhibiting it from binding p65, an
important activator of NF-%B. A similar mechanism might be happening with
Cited2 and p300 resulting in no change in activity, instead of repression, of the
NUPR1 promoter. However, there are many more instances of Cited2 and p300
working to enhance gene expression, so these transcriptional co-factors appear
to not be involved in NUPR1 expression. The conclusion from the results did not
support the hypothetical transcription factor network that Cited2 and p300
activate the NUPR1 promoter.
The next combination of transcription factors tested was the effect of IRF2
and PCAF on NUPR1 promoter activity. IRF2 belongs to the interferon regulatory
(IRF) transcription factor family and binds DNA through its N-terminal domain
[62, 67]. IRF2 binds various DNA elements such as interferon responsive
element (IRF-E), the interferon consensus sequence (ICS), and the positive
regulatory domain I (PRDI) of the IFN-" gene [63, 64, 66]. IRF2 can function as a
transcriptional repressor or activator [65].
The transcriptional cofactor p300/CBP-associated factor (PCAF) functions
as a co-activator of transcription, and it has histone acetyltransferase (HAT)
activity [73-75]. PCAF has been shown to have various functions such as acting
as a tumor suppressor and being involved in differentiation [73, 82]. IRF-2
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recruits PCAF to enhance its own binding to the ICS [83]. The direct interaction
of IRF-2 and PCAF was shown to increase the histone H4 gene promoter
activity. Since this promoter was activated by IRF-2 and PCAF, this supported
testing the effect of these transcription factors on NUPR1 promoter expression.
IRF-2 and PCAF were co-transfected with the NUPR1 promoter in the
3T3-L1 cell line. As mentioned above, the NUPR1 promoter was active in this cell
line as compared to the promoterless negative control, pGL4.10. However, coexpression of IRF2 and PCAF did not increase NUPR1 promoter activity. It has
been noted in the literature that IRF2 is acetylated by PCAF in a growing cell
type, and acetylation of IRF2 is required for promoter activation [108]. The 3T3L1 cells used in these experiments are an undifferentiated pre-adipocyte cell
type. Since acetylation of IRF2 only happens in growing cells, this transcription
factor might not be sufficiently acetylated by PCAF in the experiments testing
NUPR1 promoter activity. Stimulating 3T3-L1 cells in future transfection
experiments might exhibit NUPR1 promoter activation from IRF2 and PCAF.

THE PSP PROXIMAL PROMOTER IS NOT ACTIVATED BY MIST1
TRANSCRIPTION FACTOR IN THE PARC10 CELL LINE.
The next interaction tested to validate the hypothetical transcription factor
network was the effect of Mist1 on the PSP promoter. PSP is highly expressed in
acinar cells of the adult parotid gland [14]. Mist1 is a bHLH transcription factor
expressed in many tissues that binds to E-box sequences, -CANNTG-, as a
homodimer or heterodimer [84-86]. The hypothesis was Mist1 would activate the
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PSP promoter. The goals were to first test PSP promoter activation from cotransfection of Mist1 cDNA. The second goal was to mutate Mist1 binding sites,
or E-box binding sites, in the PSP promoter to determine promoter activity.
There were two objectives for testing the effect of Mist1 on PSP promoter
activity. The first goal was accomplished by co-transfecting PSP promoter DNA
with Mist1 cDNA in ParC10 cells. The second goal was accomplished by
mutating –CANNTG- E-box binding sites in the PSP 2kb promoter construct
(Figure 11). The non-mutant and mutant constructs were co-transfected with
Mist1 cDNA in ParC10 cells. The non-mutated PSP promoter and the E-box
mutated PSP promoter constructs were all repressed by Mist1. One reason this
repression might have happened is that Mist1 homodimers repress gene
expression. An example is MyoD repression by Mist1 homodimers during
myogenesis [109]. The Mist1 homodimer directly binds to E-box sequences in
the MyoD promoter and subsequently represses gene expression. In the
experiments testing PSP promoter activity, Mist1 does regulate the PSP
promoter, but not in the expected direction. This may be one aspect of controlling
the timing of PSP expression during development. The conclusion was the
results do not support the hypothetical network that Mist1 activates the PSP
promoter. This conclusion led us to determine other ways Mist1 could be
activating PSP.

PSP IS ACTIVATED BY A COMBINATION OF MIST1 AND TCF3
TRANSCRIPTION FACTORS THROUGH THE SECOND AND THIRD INTRON
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As mentioned above, Mist1 repressed the PSP promoter, and the
repression might have been due to formation of Mist1 homodimers. In contrast to
this finding, Mist1 has been reported to activate genes by forming heterodimers
with the E-box protein Tcf3, or E2A [84]. The E2A gene encodes two class I
bHLH transcription factors, E12 and E47, and binds E-box consensus sequences
as does Mist1 transcription factor [84-86, 95]. The E2A transcription factor is
expressed in various tissues and can act as a transcriptional activator or
repressor depending on its binding partner and other co-activators or corepressors [86]. The finding that Mist1 and Tcf3 can form heterodimers led to the
hypothesis that co-transfecting a combination of Mist1 and Tcf3 will activate the
PSP promoter.
To test the hypothesis, transient transfection experiments were performed
testing the effect of the combination of Mist1 and Tcf3 transcription factors on
PSP promoter activity in ParC10 cells. The PSP promoter was not activated by
the combination of transcription factors. The conclusion from this result was Mist
and Tcf3 are not acting through the promoter region of PSP. Again, PSP is not
exhibiting activation even though Mist1 has a dimerization partner that has been
shown to activate gene expression. The next step was to find another way to
express the PSP promoter.
One group found the gene Mindbomb-1 was activated by Mist1 through
the first intron [48]. The PSP gene was analyzed and E-box binding sites were
found in the second, third, and fifth introns of PSP. The evidence that Mist1
activates a gene through the first intron, and the analysis of the PSP gene helped
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formulate the hypothesis that a Mist1 and Tcf3 transcription factor combination
activates PSP through the intron regions. The PSP promoter + intron clone was
made by ligating a PCR amplified region between exon two and four into the PSP
1.5 kb promoter clone (Figures 10 & 13). This clone was co-transfected with
Mist1 and Tcf3 cDNA in ParC10 cells, and promoter + intron activity was
determined by performing luciferase and cypridina assays. The data observed an
increase in PSP promoter + intron activity when Mist and Tcf3 were cotransfected. The hypothetical network was supported by this result. A novel
discovery from this result was Tcf3 interacts with Mist1 to activate the PSP
promoter. This hypothetical network did not predict this interaction, and the
conclusion was that Mist1 required Tcf3 to promote PSP gene expression.
Since the combination of Mist1 and Tcf3 promoted PSP expression, the
next goal was to test the specific effect of Mist1 alone and Tcf3 alone. The PSP
1.5 kb promoter without the intron region was used as a negative control in these
experiments because it was found to have no change in activity with a Mist1/Tcf3
combination. The promoter exhibited no change in activity from Tcf3 alone, which
was a new finding, and from the combination of Mist1 and Tcf3, which was
expected. Mist1 alone repressed PSP 1.5 kb promoter activity, which was
consistent with the results described above. The results for the PSP 1.5 kb
promoter made it a valid control to compare the effects on the PSP promoter +
intron construct. The PSP promoter + intron was slightly activated by Tcf3 alone,
but not significantly, and it exhibited no change in activity when Mist1 alone was
co-transfected. Again, the PSP promoter + intron construct was activated by the
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combination of Mist1 and Tcf3 through the second and third introns, further
supporting the hypothetical network with the new finding that Mist1 requires Tcf3
for PSP gene activation. The work reported that used a Mist1 knockout mice
model supports the importance of Mist1 and the effect it has on secretory granule
formation and the content of secretory granules [93, 94]. PSP is a protein found
in parotid acinar cell secretory granules [102]. PSP activation by Mist1 could be
happening just before or simultaneously with secretory granule formation,
reiterating the importance of this transcription factor during parotid gland
development.

CONCLUSION
Even though many interactions tested did not confirm the hypothetical
transcription factor network of parotid differentiation, activation of the PSP
promoter + intron clone by Mist1 was confirmed. The next step after determining
this activation will be to confirm the Mist1/Tcf3 binding sites in the intron region
by site-directed mutagenesis. This will validate that activation is from these
transcription factors acting directly at the binding site, and it can determine if
there is a preferential binding site. This future work will be done in the laboratory,
but there could be clinical use of confirming transcriptional interactions.
Parotid gland ablation from head and neck radiation therapies, infection,
inflammation, medications, and Sjögren’s Syndrome (SS) can be debilitating [5,
15]. Patients suffering from any of these conditions lose proper parotid gland
function and will develop xerostomia [17]. This can lead to a declining oral health
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resulting in periodontitis and cavities. Determining the genes involved in parotid
differentiation could aid in the development of therapeutics involving molecular
targets and in developing improved diagnostics. Although numerous transcription
factor pathways still need to be validated, the successful confirmation of PSP
promoter activation by Mist1 and Tcf3 is a stepping-stone to the development of
gene therapies and enhancing diagnostic tools. My work, together with other
reports, suggests that transgenic expression of Mist1 may help maintain parotid
function in patients.
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